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NOVEL THERMAL ANALYTICAL TECHNIQUES TO CHARACTERIZE 
DRUGS AND DRUG DELIVERY  
LAKSHMI SWETHA KAZA 
ABSTRACT 
     This thesis encompasses three significant projects. The study includes the 
characterization and evaluation of the properties of a commercial contraceptive 
transdermal patch, Ortho Evra
®
 by Dielectric Analysis and Differential Scanning 
Calorimetry (DSC). This study helps in monitoring the mobility of the drug and transport 
properties by Isothermal and Scanning Dielectric Analysis as a function of temperature 
and frequency. The drugs in this product are norelgestromin and ethinyl estradiol. DSC 
was used to detect any crystalline character of the drugs by their fusion properties. 
Having no melting endotherm and detecting a glass transition temperature suggested that 
the drugs in the patches were amorphous. The amorphous form of the drug has more 
bioavailability. The isothermal DEA a plot of Log frequency vs. reciprocal temperature 
(K) revealed two critical modulating frequencies at body temperature 37°C for the 
two API drugs with DEA peak frequencies at 460 and 560 Hz.   
The main project includes studying the polarization of macro and micro molecular 
liquid drugs by Dielectric Analysis, B-Cell (a customized isothermal dielectric device) 
and Differential Scanning Calorimetry.  This study demonstrated in vitro transport of 
selected non-ionic high (e.g. insulin) and low (e.g. Diphenhydramine) molecular weight 
drugs through excised biological tissue membranes using alternating current (AC) 
electrokinetics. This new technique of the drug delivery system enhances benefits over 
systemic oral therapies, in which clinically sufficient quantities of the active ingredient 
 v 
 
do not reach the intended target organ and/or use of the drugs result in serious side 
effects. An optimally-tuned low-voltage applied AC electrical field has been found 
capable of inducing polarization and delivering micro and macromolecules through a 
biological membrane. The relationships between factors such as delivery time, AC 
voltage amplitude and frequency, and transported drug concentration were investigated.  
A
 
factorial design was used to establish experimental parameters for the insulin solution 
evaluating DEA variables of voltage, frequency, time, temperature, drug dose, and 
membrane thickness. A clear result of the experimental design for insulin was that the 
low frequency was significant in enhanced drug delivery. Dielectric Analysis was used to 
modulate the drugs delivery response measured by a change in the log conductivity vs. 
log frequency curve at a lower frequency of 500 Hz and a higher frequency of 1000 Hz 
for insulin at 37ºC. Imposition of a low frequency of 500 Hz aliened dipoles and higher 
frequency aided the mobility of the drug ions into the biomembranes. The delivery was 
confirmed qualitatively and quantitatively by enhanced conductivity for the drugs based 
on the ―polaron theory‖ of conductivity or the ―hopping model‖ and UV spectroscopy. 
The third project includes a study to develop a standard protocol to determine the 
water content and type by thermal analysis of Milk of Magnesia. Differential Scanning 
Calorimetry (DSC) and Thermal Gravimetric Analysis (TGA) were used in a novel 
manner for examining the commercial pharmaceutical suspensions and to note the 
difference between the brand and the generic forms. 
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OBJECTIVES 
     The main objective of this thesis was to study the polarization of macro 
and micro molecular liquid drugs by Dielectric Analysis, a customized B-Cell and 
Differential Scanning Calorimetry. Evaluation of a commercial contraceptive transdermal 
patch, Ortho Evra
®
 using DEA aided in monitoring the mobility and transport properties 
of the two drugs transdermally. DSC supplied information on the amorphous content of 
the drugs, the low density polyethylene backing substrate that melted at 106
o
C, and the 
Tg at -20
o
C of the adhesive suggests styrene butadiene rubber (SBR) latex in a low 
molecular weight resin. 
  The delivery of the drug was confirmed quantitatively by recording the enhanced 
conductivity of the drug in the bio-membrane and the drug throughput by calibrated UV 
analysis. DEA was used to modulate the drugs delivery response measured by a change 
in the log conductivity vs. log frequency curve at a low and a higher frequency. The 
consequence of this Ortho Evra research helps in developing an AC electrified 
transdermal patch for Diabetic patients in which there is a controlled release of insulin to 
be associated with a consumer‘s blood glucose level. 
Thermal Analysis aided in the development of a protocol to distinguish the water 
content in the brand and generic forms of commercially available Milk of Magnesia 
suspension and by difference in the total mass minus the water content revealed the 
magnesium hydroxide content. 
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HYPOTHESIS 
         The transdermal route provides continuous mode of administration of the drug 
especially for protein and peptides having short half-lives.  Skin is low in proteolytic 
activity thus minimizing the degradation of the drug at the site of administration. 
Transdermal patches are available in market for various drugs, but are limited to small 
lipophilic molecules which can passively diffuse through the skin. Hydrophilic and 
macromolecular drugs have low skin permeability in which electrical forces aids in drug 
transport across the skin.  Iontophoresis which uses Direct current (DC) is the most 
commonly used electrical forces for transdermal patches. A number of adverse effects are 
reported as a result of high applied voltages causing skin irritation and erythema. 
However, this approach results in uncomfortably long treatment times. Iontophoresis 
replaced by AC electric field would be a novel method for the drug delivery minimizing 
the adverse effects. It is important to have a sensitive method to characterize the transport 
properties of the drugs by AC electric field. The commercial DEA instrument and the 
customized B-cell yielded electrical properties of the drugs and their behavior and 
performance in the drug delivery. Throughput in our study is based on an evaluation of a 
closed system and measuring the drug content by UV Analysis. The DEA conductivity of 
the aqueous solution drug at the end of test should be related to the efficacy of the drug 
delivery. Basic transdermal patch material and transport properties can be determined. 
Evaluation of a commercial patch will discover the fundamental properties needed for the 
patch development. 
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PROTOCOL 
Characterization and Transport Properties by Thermal– Bio-analytical Techniques 
Synopsis 
 Characterization of commercial contraceptive transdermal patch, Orthoevera™ 
 Study the transport properties and polarization of macro and micro molecular 
drugs. 
Terminology 
 All the  significant terms are well defined 
 Defined all abbreviations  
Scope 
 Qualitative and Quantitative measurements (DEA and UV) 
 Physical and electrical properties of the drugs are evaluated 
Hazards 
 Care should be taken in handling specific drugs 
Methods 
 Dielectric Analysis 
 Ultraviolet –Visible spectrometry 
 Differential Scanning Calorimetry 
 Thermalgravimetry 
 Lab wave 9000 Moisture Analyzer  
  Oven dry method 
Summary of Methods 
 Instruments used in this study are briefly described 
 xix 
 
 Test method principle 
Calibration 
 Detailed instructions of calibration of the instrument are cited 
Significance in Use 
 New approach for the Development of Transdermal Patches 
 Study of the Drug properties 
Procedure 
 Standard protocols were performed for calibration of instruments 
 Describe successive steps for all the procedures 
Interpretation of results 
 Directions for evaluating the results 
 List of all the tables 
 Specify significant figures 
Research report 
 Detailed information required in reporting the results 
 Correlating the results 
References 
 References to publications providing needed information 
 Keywords: Identify words, terms or phrases that best represent the technical 
information reported 
Conclusions 
 Summarize all collected data 
 Compare data from different methods 
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  CHAPTER I 
          INTRODUCTION 
Transdermal drug delivery has made significant contribution to medical field, 
standing as a better alternative to oral drugs and to the use of hypodermic injections too. 
The use of topical medications to treat local infections on skin was in practice from many 
years but the use of transdermal delivery system was becoming a well known practice 
from a few decades. The scopolamine patch to treat motion sickness was first of its kind 
to be formulated as a transdermal drug. Later the use of nicotine patches has become 
popular to aid smoking cessation. Currently there are about 19 different transdermal 
delivery systems available for hormones such as estradiol and testosterone and analgesics 
such as fentanyl. Combination patches are available for contraception and hormone 
replacement therapy.[1]  Some of the most commonly used transdermal patches are as 
follows: nicotine patch which releases nicotine for about 16 hours and prevent the 
carving of cigarette by smokers, scopolamine patch which shows the effect for about 3 
days, used to treat motion sickness and also in post operational nausea, fentanyl patch 
which has its pain relieving effect for about 72 hrs and estrogen-progestin contraceptive 
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need to be taken only once a week rather than taking a pill every day.[2] This extended 
release formulation provides better patient compliance. 
Advantages 
Transdermal systems are non-invasive and can be self-administered. Controlled 
release of the medication is one of the advantages over other formulations like oral and 
topical. It prevents gastrointestinal irritation which is more common effect seen with oral 
formulations. This route of drug delivery bypasses the first pass effect of the liver which 
is a potential advantage over oral formulation of drugs. It avoids multiple dosing of drugs 
thus enhances patient compliance. They also improve patient compliance and the systems 
are generally inexpensive. 
Barrier 
But one of the major drawbacks of this system is that skin being an effective 
barrier; it is restricted only to the delivery of certain low molecular weight, lipophilic 
drugs.  The exploitation of transdermal drug delivery for the delivery of hydrophilic 
drugs, peptides and macromolecules always remained as one of the great challenges. Skin 
is composed of outer thick layer, stratum corneum which is about 10-20 µM thick. Below 
this layer is epidermis which lacks blood vessels and measures about 50-100 µM. The 
underlying layer beneath the epidermis is dermis which has blood capillaries suitable for 
drug absorption. The major hindrance for the drug particles is stratum corneum, 
composed of corneocyte cells cross-linked with keratin and intracellular spaces are filled 
with a mixture of lipids arranged in bi-layers. Transport of drug particles through this 
complex structure is a great ordeal that is faced. This necessitates the use of enhancers 
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that facilitate the transport of drug molecules by enhancing permeability of stratum 
corneum.  
Stages of transdermal drug development 
The first generation transdermal drug delivery involved the delivery of lipophilic 
and small molecules using traditional patch system. A typical scopolamine patch has an 
outer backing layer which is impermeable, underneath of which a drug reservoir is 
present. [1] Then a rate limiting membrane is present which controls the rate of drug 
delivery from the reservoir, followed by an adhesive layer that sticks to the skin. A 
protective layer is present which is removed just before using the patch. This generation 
has been successful in delivering certain drugs.  
The second generation advanced a little bit by using conventional chemical enhancers to 
deliver other hydrophilic molecules. The enhancers used include Azone (1-
dodecylazacycloheptan-2-one) and SEPA (2-n-nonyl-1,3dioxolane).[2] But the use of 
chemical enhancers is not very much successful in delivering hydrophilic and macro 
molecules because  these chemicals disrupted the inner skin layers. Other techniques like 
iontophoresis and non-cavitational ultrasound have also been used. Iontophoresis increase 
transdermal drug delivery by typically applying a continuous low-voltage current. 
Iontophoresis does not affect the skin permeability but enhances drug transport by 
providing an electrical driving force which makes it as an adjuvant method. [3,4]  
Because Iontophoresis does not primarily change the skin barrier itself, it is mostly 
applicable to small molecules that carry a charge and some macromolecules up to a few 
 4 
 
thousand Daltons, so this technique could not be an ideal technique for the delivery of 
macromolecules and vaccines. 
The third generation made use of cavitational ultrasound, Micro needles and 
electroporation methods which are based on the principle of disrupting stratum corneum 
on a nanometer scale. [5] Ultrasound generates cavitation, which is the formation, 
oscillation and, in some cases, collapse of bubbles in an ultrasonic pressure field.[6] This 
cavitation bubbles concentrate the energy of ultrasound and thereby enable targeted 
effects at the site of bubble activity for the transdermal drug delivery.[7]  Although 
effective, applications of cavitational ultrasound may be limited by the need for a 
sophisticated device that only increases skin permeability at the nanometer scale and 
thereby may not be broadly applicable to macromolecules and vaccines. Electroporation 
uses short, high-voltage pulses, a method to reversibly disrupt cell membranes for gene 
transfection and other applications. It has shown to disrupt lipid bi-layer structures in the 
skin
.
[8]
 
During electroporation the electric field applied for milliseconds provides an 
electrophoretic driving force. Diffusion through long-lived electropores can persist for up 
to hours, such that transdermal transport can be increased by orders of magnitude for 
small model drugs, peptides, vaccines and DNA [9]. Recently, electroporation was shown 
to deliver a model peptide vaccine into the skin of mice to generate a strong cytotoxic T 
lymphocyte response.[10] Although electroporation has been studied extensively in 
animals, this approach to transdermal delivery has received limited attention in humans 
because of  the complexity of device design. 
Limitation of diffusing large compounds through micron-scale disruptions, a long 
time to diffuse through, longer treatment times, a very small amount of transported 
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molecules, and therapeutically insufficient amount of drug passing through in the 
majority of applications leads us to develop novel thermal analytical techniques to 
characterize drugs and drug delivery. The main goal of this study is to investigate various 
variables and optimize the conditions such as length of treatment and low currents for 
effective transdermal drug delivery of macromolecule e.g. insulin. 
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CHAPTER II 
INSTRUMENTATION 
2.1. Dielectric Analysis 
 Dielectric Analysis (DEA) is a thermo analytical technique used to measure changes in 
electrical properties of a sample, liquid or solid, as a function of temperature, time, and 
frequency. The two fundamental electrical characteristics that DEA can measure for a 
sample are Capacitance (High frequency permittivity  e‘) or dielectric constant) and 
Electrical conductivity (pS cm
-1
)  Loss factor  e‖) * applied frequency  Hz) * a constant). 
DEA measures three main parameters over a wide range of frequencies (e.g. 0.10 to 
300,000 Hz):  the loss factor (e”) which is related to the energy required to align dipoles 
and move ions and is converted into the ionic conductivity (pS/cm). The permittivity (e’) 
is another physical property and is related to the dipole content. Tan Delta is a ratio of 
loss factor divided by the permittivity,  e‖/e‘).  An applied sinusoidal voltage on a sample 
placed on a sensor creates an alternating electric field, inducing polarization of the 
sample and followed by facilitate transport of the polarized drug through a bio-
membrane. 
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Figure 1: TAI Dielectric Analyzer 2970 
 Isothermal DEA procedure determines the polarization time of a sample and helps 
in better understanding of the chemistry and molecular mobility that relates to the 
structure of the drug. DEA is ultra-sensitive, and can measure conductivity from 10
-
3
 pScm
-1
 and as high as 10
12
 pScm
-1
. DEA measures changes in dipole orientation and ion 
mobility of the sample. 
2.1.1. Instrument 
     Dielectric Analyzer (DEA) TA instrument (TAI) 2970 was used in this study. 
Parameters such as temperature, sampling size, sample placement, calibration of the 
sensor and temperature, are to be taken into consideration.  The DEA can test various 
forms of samples, i.e. gels, solutions, solids, powders, and thin films. Four types of 
sensors exist for the TA Instruments DEA: parallel plate, single surface, sputter coated 
and remote single surface. [2] Single surface gold ceramic inter-digitated electrodes are 
used for the experiments. Measurements can be taken within a temperature range of -100 
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ºC to 300 ºC and through a frequency range of 0.1 - 300k Hz. Dry nitrogen gas or air gas 
purge at a flow rate of 50 mLmin
-1
 is used. 
2.1.2. Calibration                  
                    New test procedures were applied that describes the temperature calibration 
of Dielectric Analyzers with pharmaceuticals over the temperature range from 25°C to 
250°C. This procedure uses pure Active Pharmacy Ingredients (APIs). This test method 
can be used with a universal standard protocol for DEA. This new standard test method 
can employ devices from a variety of commercial companies. Calibration is performed by 
observing the melting transition temperature of standard Pharmaceutical materials within 
the temperature range of interest. 
     Pharmaceutical test specimens (calibrants) of established melting temperatures are 
evaluated in a closed system typically in a nitrogen atmosphere over a specific 
temperature range. The test calibrants are evaluated by DEA using an interdigitated 
electrode array (IDA) over a specific temperature range. At the transition temperature of 
the test specimen, there is a change in permittivity which is recorded. These melt 
transition temperatures of test specimens obtained from DEA data are compared directly 
to the known literature melt transition temperatures.  
     The calibration materials used in this test development are: Acetanilide (Tmp, 113-
116°C) and Acetophenetidin (Tmp, 132-138°C).[7,8] These test protocols were 
accomplished based on the Standard Test Method for temperature calibration of DEA and 
ASTM E 2038 [1]. The preliminary R
2
 coefficient of correlation for known literature 
transition temperature vs DEA Permittivity melt temperature for the calibrants was 0.98. 
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These new pharmaceutical based test protocols, permit inter-laboratory comparison and 
intralaboratory correlation of instrumental temperature scale data within the 
pharmaceutical community, and will be implemented in our chemical pharmaceutical 
research.  
 
Figure 2: DEA curve of Acetanilide showing Log permittivity and Derivative of Log 
permittivity transition temperature at 1 Hz frequency.  
     A summary of frequency used i.e. (single or set of 4 frequencies); permittivity and 
Log permittivity transition temperature obtained from the DEA thermal curves of the 
calibration materials are listed in:  Acetanilide, table 1;  
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Frequency (Hz) 
Permittivity Transition 
Temperature °C 
Log Permittivity Transition 
Temperature °C 
1000 Hz 114 113 
   
1Hz 116 113 
10 Hz 115 113 
100 Hz 114 114 
1000 Hz 114 114 
   
Average 115 113 
Std Deviation 0.89 0.55 
% Relative Error 0.77 0.48 
Table 1: Acetanilide Tmp (113-116) °C; DEA Permittivity and Log Permittivity 
Transition Temperature of single and set of frequencies. 
2.1.3. Procedure 
Dielectric analysis was performed using TA Instruments DEA 2970. For DEA, the 
sample was placed on a single surface gold ceramic inter-digitated electrode and heated 
to isothermal temperatures. The procedure includes ramp at 5
o
C min
-1
 to 37
o
C and held 
isothermal for 45 minutes with a flow rate of 50 ml min
-1
 in nitrogen. Shedded snake 
skin, a black snake skin (and pig skin were used in this study as a barrier for the transport 
of insulin using an AC electric filed. DEA measures the electrical properties of the drugs 
used in this study as a function of time, temperature, and frequency. Ionic conductivity 
was then measured as a function of DEA variables to obtain permittivity [e‘], dielectric 
loss [e‘‘] and loss tangent [tan delta=e‘‘/e‘]. Permittivity is proportional to the 
capacitance and measures the number of dipoles. Loss factor is proportional to the 
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conductance and represents the energy required to align dipoles and move ions by the 
hopping model (Polaron theory). Ionic conductivity relates to the viscosity of the sample 
because fluidity is identified by the ease with which ionic components can migrate 
through the sample under the applied electric field. 
2.2 Differential Scanning Calorimetry 
 Differential Scanning Calorimetry (DSC) is a thermoanalytical technique which 
measures the difference in heat flow rate between a sample and reference as a function of 
temperature. Both the sample and reference pans are maintained at nearly the same 
temperature throughout the experiment. Differences in heat flow occur due to the heat 
capacity of the sample which increases with temperature. The fundamental principle 
underlying this technique is that, when the sample undergoes a physical transformation 
such as phase transitions, less or more heat must flow to the sample depending on 
whether the process is exothermic or endothermic. When less heat is required to raise the 
sample temperature, there is a result of release of heat which results in exothermic 
transitions. Crystallization and decomposition involves exothermic process. When more 
heat flow is required to the sample to increase the temperature at the same rate as the 
reference heat is absorbed resulting in endothermic transitions. Melting, glass transition, 
and evaporation involve endothermic process. 
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                     Figure 3: TAI DSC 2920                     Figure 4: Mettler DSC 823
e
 20 
  DSC is widely used in the Pharmaceutical industries to characterize the drug 
compounds in order to define processing parameters. The amorphous form of the drug is 
a more efficient drug delivery material and is more bioavailable, but is less stable. It is 
desirable to process the drug at temperatures below those at which crystallization can 
occur. DSC also helps in providing changes in the water distribution correlated with the 
water and solute interactions in a solvent.  Application of DSC with respect to 
Pharmaceutical drugs and chemicals include melting temperature (Tm), Glass Transition 
temperature (Tg), Glass transition size, crystallization temperature (Tc), crystallinity (Jg
-
1
), and Polymorphic Transitions (Figure 5). 
 14 
 
 
   Figure 5: Transitions in a DSC Curve 
2.2.1 Instrument     
The TAI DSC 2920 and Mettler DSC 823
e
 were used to measure the heat flow 
properties of pharmaceutical drugs as a function of time and temperature.  The 
experimental parameters like sample size, environment, heating rate and pan type (open 
pan, closed pan etc.). Solid Fat Index aluminum pans (Figure 6) are used in this study. 
Sampling size can vary ranging from 2 mg to 15 mg, heating rates ranging from 1
o
C min
-
1
 to 100
o
C min
-1
. The performance of DSC is dependent on all these experimental 
variables.  
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Figure 6: Solid fat index (SFI) pans used for DSC; left- pan, right- lid 
  DSC operates over a temperature range of -100 to +300
o
C for pharmaceuticals. DSC 
plots are obtained as the differential heating flow (in units of watts sec
-1
, joules sec
-1
 or 
calories sec
-1
) with respect to temperature. Purge gas; typically Nitrogen (sensitivity) or 
Helium (resolution) is used at a flow rate of 50 mL min
-1
 and liquid nitrogen cooling 
when going below the room temperature. 
2.2.2 Calibration 
Calibration of the instrument is essential to have better consistency in results 
obtained. DSC instrument calibration involves Differential Heat Flow, Temperature and 
Baseline. Following the ASTM E968 method [4], Differential heat Flow is calibrated. 
The characteristic temperatures and the enthalpy associated with a phase change of the 
standard were compared to the literature values [7,8] (Figure 7). Heat flow calibration 
should not change with heating rate. 
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Figure 7: Differential Heat Flow calibration curve for Acetophenetidine showing 
Tm and Tmp 
Following the ASTM E967 protocol [5], the temperature of the instrument is 
calibrated. High purity calibration standards such as Indium, Acetanilde [7] and 
Acetophenitidine [8] are used for the calibration. DSC Baseline Slope is also calibrated. 
2.2.3 Sampling 
Sample shape, size and weights are to be considered during the packing of sample 
in the aluminum pan for the DSC run. Sample should be as thin as possible, distributed 
throughout the pan to have good thermal contact and cover as much of the pan bottom as 
possible. The thin solid sample can be obtained by cut rather than crushed. A liquid 
sample is placed in contact with the aluminum pan. A consistent DSC curve can be 
obtained if there is a good thermal contact of sample with the base of the pan. The 
experiment can be conducted with an open pan, covered pan or sealed pan and the pan 
can be either a standard pan which has a flat base or a SFI pan that has crimped base and 
the reference pan with similar configuration. Crimped pans always have the highest 
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sensitivity and resolution. The sample size can vary ranging from 2 mg to 15 mg and 
should be weighed before and after the experiment to observe any mass loss upon 
heating.  
2.2.4 Procedure 
     Calibration of the instrument is the initial step and was performed by following the 
ASTM standard protocol. Samples were weighed and placed in a SFI aluminum pans 
with sampling size ranging from 2 mg to 15 mg. Open and closed pans were used in this 
study depending on the nature of the sample e.g. solid or liquid. The samples were cooled 
from 25 to -50
°C and then heated to 120°C at 5˚Cmin-1 heating rate with nitrogen gas 
purge of 50 mL min
-1
 for the study of liquids.  Samples were heated to 30
°
C above the 
melting point for solids to see the endothermic process and cooled to 50
°
C below the 
melting point to see the exothermic crystallization process. A DSC scan usually provides 
the following thermal properties: the Heat of Fusion  ∆Hf), melting temperature (Tm), a 
peak melt temperature (Tmp), Heat of Crystallization  ∆Hc), crystallization temperature 
(Tc), a peak crystallization temperature (Tcp), Heat of Vaporization  ∆Hv), vaporization 
temperature (Tv) and a peak vaporization temperature (Tvp). 
2.3 Thermal Gravimetric Analysis (TGA) 
     Thermogravimetric analysis (TGA) or Thermogravimetry (TG) is a thermoanalytical 
technique used to determine changes in weight of a sample as a function of temperature 
or time (isothermal TG). A sample of exact weight is heated in a special instrument at a 
given rate (˚Cmin-1) through a measured mass loss attributed to either of the following: 
dehydration, solvent or solute desorption, a gaseous product formation from a reaction 
e.g. loss of carbon dioxide from calcium carbonate with a residue of calcium oxide or 
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decomposition of the sample. Such analysis relies on a high degree of precision in three 
measurements: weight, temperature, and temperature change.  
 
                            
                              Figure 8: Thermogravimetric Analyzer 
The first derivative of the weight vs. temperature curve (DTG) highlights key 
transitions or changes in the sample more definitively for enhanced interpretation. TG is 
typically employed in research to characterize pharmaceuticals, chemicals, biological 
entities or polymers. Combining TG with DSC measures endothermic processes a 
function of temperature or time in a controlled atmosphere. The data obtained 
differentiates endothermic and exothermic transitions with no associated weight loss 
(e.g., melting and crystallization) and those that involve a weight loss (e.g., degradation). 
2.3.1 Instrument 
    A TA Instruments Hi-Res TGA Model 2590 TG analyzer was used in these studies. It 
consists of a high-precision balance with a pan loaded with the sample. Regular heating 
of furnace and the sample holder up to 800°C in air for 10-15 minutes should be done to 
keep them clean from organic residues. The sample is placed in a small electrically 
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heated oven with a thermocouple to accurately measure the temperature. The atmosphere 
may be purged with an inert gas to prevent oxidation or other undesired reactions.      
 
2.3.2 Sampling and Procedure 
     The samples were prepared by placing one drop of material on to a pre-tared platinum 
TG pan. The pan was placed onto the auto-loading mechanism of the TG analyzer and an 
automated loading sequence was initiated. The sample is placed into a furnace which 
heats the sample, while measuring the weight of the sample every 0.5 seconds. The TG 
experimental conditions were: Ramp 10°C per minute to 500°C in nitrogen as purge gas 
at a flow rate of 50 ml min⁻¹.  30-50mg of sample was used in each run. An inert 
atmosphere, usually high purity dry nitrogen, is purged to prevent oxidation or other 
undesired reactions. Then the data is analyzed using TA software. 
TG rapidly measures changes in weight as a sample is heated and is eventually 
vaporized. This can be used to create a water loss profile that can show the different 
temperature ranges in which water and other components of a sample vaporize.  
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CHAPTER III 
CHARACTERIZATION AND PROPERTIES OF AN ORTHO 
EVRA
®
TRANSDERMAL PATCH AND LIDOCAINE BY ISOTHERMAL & 
SCANNING DEA 
Abstract 
 An ideal delivery system must include a steady and prolonged therapeutically 
effective drug concentration with or without minimum side effects. Unique modern 
methods of drug delivery are turning to transdermal or transoral patches. A great deal of 
research is being devoted to comprehend and smooth the progress of the growth of a 
transdermal absorption scheme. The focus of this research is the monitoring of the 
mobility of drugs and transport properties by Dielectric Analysis. DEA is used to track 
the drug and drug transport as a function of temperature and frequency. Our first study 
included characterizing a commercial contraceptive transdermal patch, Ortho Evra
®
 by 
thermal analytical techniques. The drugs in this product are norelgestromin and ethinyl 
estradiol. DSC was used to detect any crystalline properties of the two drugs by their melt 
properties. Having no melting temperatures due to the drugs and detecting a glass 
 22 
 
transition suggested that the drugs in the patches were amorphous. If they are amorphous 
they are more bio-available. DSC also aided in identification of the polymeric adhesive, 
the polymer backing and the drug properties. The isothermal DEA revealed critical 
modulating frequencies at body temperature of 460 and 560 Hz for the two drugs. 
 Lidocaine is an anesthetic prominently used in dental procedures. DSC and DEA 
properties of Lidocaine have led to a better understanding of transdermal and transoral 
drug delivery. Lidocaine was evaluated by scanning DSC, isothermal and scanning DEA. 
Scanning DSC results at the standard heating rate 10˚Cmin-1 were Tm 74˚C and Tmp 
81˚C. At higher heating rates the melt temperatures were shifted to higher values tm 84˚C 
and Tmp 89˚C. Heat of fusion was 138jg-1 and there appears no shift in the values with 
higher heating rates. Scanning DEA determines the amorphous and crystalline forms of 
the Lidocaine with respect to temperature. Testing of pure Lidocaine revealed that the 
amorphous form is several order of magnitude more conducting that the crystalline 
Lidocaine. Isothermal DEA determined the Critical frequency for Lidocaine transport 
through the shedded snake skin at a frequency 70 to 100 Hz. This data is critical to the 
development of an effective transoral patch.  
Key words: Transdermal patch, Transoral patch, Dielectric Analysis, Critical Frequency, 
Differential Scanning Calorimerty 
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3.1 Introduction  
 An ideal delivery system must include a steady and a prolonged therapeutically 
effective drug concentration with or without minimum side effects. A unique modern 
method for drug transport is employing a transdermal patch. [1]The market for 
transdermal drug delivery is over $3 Billion annual, just in the US, with this estimation 
including only the traditional patch markets such as Lidocaine, Nicotine and Estradiol. 
This type of patch avoids the chemically hostile gastrointestinal environment, has 
reduced systemic side effects and sometimes has improved efficacy over other dosage 
forms [4]. In addition since transdermal patches are user friendly, convenient, painless 
and offer multi-day dosing, it is generally accepted that they offer improved patient 
compliance [7].       
 Ortho Evra
®
, a commercial transdermal patch has 6.00 mg of norelgestromin and 
0.75 mg of ethinyl estradiol as the API drugs.  Molecularweight of norelgestromin is 
327.47 and that of ethinylestradiol is 296.41. The patch is a thin, matrix-type consisting 
of three layers: the backing layer, middle layer and the release liner.  
 
 The backing layer is a flexible film which helps in supporting and protects 
the middle adhesive layer from the environment.  It has a low-density pigmented 
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polyethylene outer layer and a polyester inner layer. The middle layer contains the active 
components; the two drugs norelgestromin and ethinylestradiol, and the polymer, Styrene 
Butadiene Rubber (SBR) latex as a low molecular weight resins an inactive components. 
The third layer is the release liner, which protects the adhesive layer (backing material) 
during storage and is removed prior to the application of the patch. In this study we 
determined the DSC and DEA properties of each drug.[5] DSC was used to detect any 
crystalline drugs by their fusion properties. The research protocol was to determine the 
Critical frequency of each drug in the patch on a Shedded Snake Skin at body 
temperature as a function of ionic conductivity and time. DEA determined the ionic 
conductivity of drugs in the patch since it was our hypothesis that the ionic conductivity 
was directly related to drug delivery from a transdermal patch.  
Lidocaine is a local anesthetic and antiarrhythmic drug. Lidocaine patches are 
used to relieve the pain of post-herpetic neuralgia. It works by stopping nerves from 
sending pain signals. Lidocaine is used topically to relieve itching, burning and pain from 
skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor 
surgery. Lidocaine molecular weight is 234.34 da. 
 
   Lidocaine 
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 Bioavalability of Lidocaine when taken orally is 35% and 3% when used for 
topical administration. Adverse drug reactions (ADR) of Lidocaine when used as a local 
anesthetic and administered correctly have rare side effects. Most ADRs associated with 
lidocaine for anesthesia relates to administration technique [13] and hence a great deal of 
research is being devoted to comprehend and smooth the progress of the growth of a 
transdermal absorption scheme. The continued focus of this research is the monitoring of 
the mobility of drugs and transport properties by Dielectric Analysis. DEA is used to 
track the drug as a function of temperature and frequency. DEA properties of Lidocaine 
have led to a better understanding of transdermal and transoral drug delivery. Dielectric 
relaxation processes [tan delta (loss factor/permittivity) vs. temperature] associated with 
drug transport/activity in each patch were detected at body temperature. It appears that 
the DETA properties are related to drug diffusion from the polymeric patch through the 
bio-membrane to the gold ceramic interdigitated sensor. 
     
3.2 Experimental Procedures 
A TAI 2920 DSC employing a cool-heat-cool cyclic procedure at 10°Cmin
-1
 in 
Nitrogen with closed-crimped aluminum pan and  a typical 5 mg sample size.  Lidocaine 
melt temperature is 74-81
o
C. We also evaluated Ibuprofen with and without the shedded 
snake skin. The commercial OrthoEvra
®
, the birth control patch was also evaluated to 
verify the experimental conditions.  
A TAI 2970 Dielectric Analyzer  was used with a ramp of 5°Cmin
-1
 in Nitrogen 
with single surface sensor interdigitated array gold ceramic electrodes were used to 
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collected electrical properties of the Dentipatch®, USP Lidocaine, and USP Ibuprofen. 
The TAI 2970 DEA was also set in the isothermal mode at 37
o
C employing a frequency 
sweep from 0.10 to 10000 Hz for at least 50 minutes. The latter procedure was followed 
for the Lidocaine crystalline solid by heating the sample through the melt to 100
o
C and 
then cooled to room temperature. A second DEA run of the amorphous drug was initiated 
and followed the same procedure as in the first run.  
3.3 Results and Discussion 
 The DSC evaluation of the Ortho Evra
®
 commercial patch revealed a low 
temperature Tg at -29˚C. It is our interpretation that the Tg is due to a pressure sensitive 
adhesive with a tackifier, typically used currently in commercial patches. [14] Usually the 
polymer is Styrene Butadiene Rubber (SBR) latex as a low molecular weight resin.  The 
melting characteristics at higher temperatures were identified as the polymer backing 
material of the commercial patch. The melting at 105 to 114˚C was repeated at 109 to 
116˚C. This material was isolated and further identified by quench cooling the polymer in 
liquid nitrogen, -120˚C, and further examined to find that the backing polymer was the 
only crystalline entity in the patch. Therefore, the drug component was amorphous and 
more bio-available, Figure 9 
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               Figure 9:  DSC of OrthoEvra commercial patch 
 
The scanning DEA produced a conductivity peak vs. temperature for the polymer 
backing material at 93 to 95˚C. It is interpretated as the DEA melt temperature of low 
density polyethylene which confirms the DSC results.  The peak conductivity 
temperature was constant with all frequencies and therefore implies that it represents a 
first order thermodynamic transition as a melt transition, i.e. melt of low density 
polyethylene. (Figure 10) 
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             Figure 10: DEA conductivity peak vs. temperature 
 
The Tan Delta vs Temperature plot yielded a bimodal critical peak response. (Figure 11) 
The tan delta a Debye plot values, as a function of temperature and frequency at <100˚C 
revealed a number of polarization processes due to the two drugs.   It was assumed that 
the lower four critical peak frequencies occurring at lower temperatures and the three 
critical peak frequencies occurring at higher temperatures were taken both as a different 
set of values. Our proof of concept was the plot of log peak frequency vs reciprocal 
temperature (K
-1
) would have a statistical correlation coefficient of >0.95. We observed 
for the lower temperature critical peaks the R
2
 was 0.98 (Figure 12) and R
2
 for the higher 
temperature critical frequency peaks was 0.99 (Figure 13). These curve fits were then 
used to determine a critical frequency at 37˚C by extrapolation for the two drugs. Based 
on the functional group analysis and evaluation of the dielectric constant of the two drugs 
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we assumed the lower peak frequency values were associated with ethinyl estradiol and 
high peak frequencies were that of norelgestromin. The results are   460 Hz for ethinyl 
estradiol and 562 Hz for norelgestromin.  These critical frequency determinations were 
confirmed by plotting Log ionic conductivity vs time and then determining the log 
conductivity vs log frequency at 37˚C and at a time period of 20 min (Figure 14). The 
deviation in this latter plot was determined and found to be within 10% the same values 
for the first method to determine the critical frequencies for aiding drug delivery; both 
methods gave critical frequencies of ca. 500 to 600 Hz to push the drugs from the patch 
into skin. The isothermal DEA revealed a critical modulating frequency at body 
temperature.  
 
              Figure 11: Tan Delta vs Temperature plot bimodal critical peak frequencies  
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Figure 12: log peak frequency (Hz) vs reciprocal temperature (K
-1
) 
           
 
Figure 13: log peak frequency (Hz) vs reciprocal temperature (K
-1
) 
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      Figure 14: Log Conductivity (pScm  ¹) vs Log Frequency (Hz) Ortho Evra patch 
 
Lidocaine, an analgesic, was also examined by DSC and DEA. The melt profile as 
a function of heating rate is disclosed in Figure 15. The DSC results at the standard 
heating rate 10 Cmin-1 were Tm 74˚C and the Tmp is 81˚C. However, when the heating 
rate was increased to 75 or 100˚Cmin-1 the Tm was 84˚C and the Tmp was 89˚C for both 
higher heating rates. The heat of fusion was 138 Jg
-1
 for the standard rate and 135, 144 
Jg
-1
 for the higher rates. Only the Tm and Tmp increased but the heat of fusion appears to 
be the same.  
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         Figure 15: DSC of Lidocaine with higher heating rates 
The DEA curves of log ionic conductivity vs. temperature for Lidocaine or 
Lidocaine.HCl were definitive in that the first run depicted a crystalline material, its solid 
state with an initial ionic conductivity of 10
-1
 pScm
-1
 at 50
o
C. The melt properties as a 
function of frequency were 10
5
 to 10
6 
pScm
-1
. The second run was clearly an amorphous 
chemical with the initial ionic conductivity starting at 10
4
 pScm
-1
 at 50
o
C and in the melt 
10
6
 pScm
-1
. The HCl salt of Lidocaine and the Lidocaine without the salt was observed to 
have the same results. 
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           Figure: 16 Lidocaine Hcl Ionic Conductivity vs. Temperature 
An alternative technique to determine the critical frequencies needed to 
manipulate the drug and push it through a bio-membrane for DEA drug transport was 
developed. First, plot log ionic conductivity vs. time and vary the frequency at a given 
temperature. At a set time of 20 min. record the log ionic conductivity vs. log frequency. 
Evaluate this last plot for significant change as an increase (the ionic drug is transporting 
through the membrane) or decrease (the drug has completely transported through the 
membrane) in the conductivity and note the critical frequency at the start of the variation. 
This initial frequency variation is the ―critical frequency”. The critical frequency for 
Lidocaine or Lidocaine.HCl was 70 to 100 Hz. This method of analysis for the critical 
frequency was tested by evaluating a drug on a shed snake skin bio-membrane and 
determining the effective drug through put by a calibrated UV analysis.   
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            Figure 17: Lidocaine Log ionic conductivity vs. time 
 
 
 
 
 
 
 
 
 
 
                 Figure 18: Lidocaine Log conductivity vs log frequency 
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From the plot of log ionic conductivity vs. log frequency for a crystalline 
Lidocaine vs. an amorphous Lidociane, one observes clearly that the amorphous form is 
more conducting than the crystalline form, which is a well known observation. (Figure16) 
 
 
 
 
 
 
 
 
 
 
               Figure 19: Log Conductivity vs. log frequency of amorphous and crystalline 
form of Lidocaine 
3.4 Conclusions 
Having no melting temperatures due to the drugs, however a melting process due to the 
backing polymer polyethylene and detecting a glass transition suggested that the drugs in 
the patches were amorphous. If they are amorphous they are more bio-available. Drug 
DEA properties proved appropriate in evaluating transdermal & oral patch drug delivery 
as monitored by Ionic Conductivity. One can scan or ramp temperature employing DSC 
and DEA to study the transdermal or oral patch for its components e.g. the polymeric 
adhesive, the polymer backing material and the active ingredient, the drugs. Alternately 
one can scan for the effect of the drugs by DEA at isothermal 37
o
C, that is, measure the 
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ionic conductivity vs. temperature and frequency range (0.1 to 5000 Hz). Unique 
dielectric properties of the Ortho Evra
®
 patch have been determined. One can modulate 
drug distribution [increase its transport through the shedded snake skin] at >600 Hz at 
body temperature. The critical frequency for the commercial patch was based on the DEA 
Tan Delta vs. Temperature and frequency plots using the Arrhenius Model. For 
Lidocaine, the modulating drug distribution frequency is at 100 Hz based on the 
isothermal DEA 37
o
C Conductivity vs. Temperature and Frequency. Transdermal and 
Trans-oral patch drugs are amorphous and drug transport monitored by ionic conductivity 
is enhanced over the crystalline drug as discovered when characterizing an Ortho Evra
®
 
patch and Lidocaine on a model skin, shedded snake skins.  
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CHAPTER  IV 
THERMAL AND BIO-ANALYTICAL CHARACTERIZATION OF AQUEOUS 
DRUGS AID THE DEVELOPMENT OF DRUG DELIVERY IN ANIMAL 
MODELS 
Abstract  
Transdermal drug delivery has many benefits over systemic oral therapies, in 
which clinically sufficient quantities of the active pharmaceutical ingredient do not reach 
the intended organ and/or use of the drugs result in serious side effects. However, 
existing transdermal platforms are limited to drugs of small size, ionic nature and low 
molecular weight. In the case of diffusion, treatment time is passively determined by the 
typically slow diffusion process rather than the therapeutic need. An optimally-tuned 
low-voltage applied AC electrical field has been found capable of inducing polarization 
and delivering micro- and macromolecules through a biological membrane. In this study, 
insulin, Diphenhydramine and Lidocaine gel were transported by AC electrokinetic‘s 
through animal models, including pig skin and shedded snake skin at body temperature. 
A factorial design was used to establish experimental parameters for the insulin solution 
evaluating variables of voltage, frequency, time, temperature, drug dose, and membrane 
thickness. Pre- and post-test conductivity measurements of the pig skin samples are taken 
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as an indicator of drug permeation and changes in conductivity are correlated with 
experimental variables to assess the relative importance of each variable to drug 
transport. Dielectric Analysis was used to modulate the drugs delivery response measured 
by a change in the log conductivity vs. log frequency curve at lower frequency of 500Hz 
and a higher frequency of 1000 Hz for insulin at 37ºC. Proof of concept for the drug 
transport was confirmed by examining a residue on the electrode by Ultra Violet 
Spectroscopy. Lidocaine gel and Diphenhydramine as formulated drugs, in an aqueous 
solution were also evaluated by the AC field to determine their transport performance. A 
clear result of the experimental design for insulin was that the low frequency was 
significant in enhanced drug delivery. Imposition of a low frequency of 500Hz aliened 
dipoles and higher frequency aided the mobility of the drug ions into the bio-membranes. 
Key words 
Transdermal drug delivery, Dielectric Analysis, UV Spectroscopy, Lidocaine gel, 
Diphenhydramine, insulin, AC electrokinetics, polarization 
 
 
 
 
 
4.1 Introduction and Background 
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Advances in biotechnology, particularly in recombinant protein technology, lead to a 
great deal of attention to the therapeutic roles of peptides and proteins. Protein and 
peptide drug delivery has been an area of intensive research because of their efficacy in 
several disease conditions [1]. Most protein and peptide drugs are currently used as 
parenteral formulations because of their poor oral bioavailability and they do not reach 
the target organ either fast enough or in high concentrations when delivered via other 
routes [3]. These drugs are usually recommended for chronic conditions, and the use of 
injections on a daily basis during long-term treatment has obvious drawbacks [9]. Insulin 
is the most important among the therapeutic proteins and peptides being explored. About 
2 million American people are suffering from hyperglycemia which requires insulin for 
the treatment. Exogenous insulin administration is basically a replacement therapy, when 
administered subcutaneously yield a plasma profile which mimics the endogenously 
secreted insulin in a normal individual. There is extensive research on several aspects of 
the insulin delivery. In recent years, there has been a great deal of interest in the 
exploitation of non-invasive routes for insulin  therapy, and their development by the 
pharmaceutical industry, including oral, nasal, buccal, pulmonary, transdermal, rectal, 
and ocular drug delivery systems [16]. The transdermal patch delivery system presents 
distinct advantages over systemic drug delivery in reducing the problem of 
hyperinsulinemia[15, 16]. This new delivery system reduces the chance of micro and 
macro angiopathy, infection and pain as well as improving patient compliance.  Injection 
dosing also has specific advantages as efficacy. The problems with injections include: 
restricted fat deposition at the injection site, which leads to local hypertrophy, inability to 
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load the syringe and administer it as well as the pain, cost and infections [21]. Therefore, 
the transdermal dosing remains a better route for drug administration. 
 Compared to other means of drug delivery, the transdermal route offers 
unique advantages: transdermal drug delivery is non-invasive; absorption is not affected 
by food intake and is not subject to first-pass metabolism in the liver [11]. In addition, 
active transdermal drug delivery systems allow precise control of drug dosing [10]. 
However the drug delivery is enhanced through modulation of an electric field (Dielectric 
Transdermal process) used to drive drug transport [4]. All transdermal drug delivery 
methods introduce therapeutic agents into the body through the skin. Drug transport can 
either be passive, relying on drug diffusion across the skin, or actively driven by 
application of an electric field [8]. The drug delivered, aided by an electric field, had 
appropriate pharmacokinetics and pharmacodynamics, and the drug was stable in the 
patch. Depending on the drug in the patch the time duration of delivery can be up to 1 to 
7 days. 
Electrically-assisted transdermal delivery is the facilitated transport of compounds 
across the skin using an electromotive force. Depending on the nature of the applied 
electric field, the molecule to be delivered and the barrier to be crossed, various 
combinations of the driving forces such as iontophoresis, electrophoresis (EP), 
electroosmosis (EO), dielectrophoresis (DEP), and others are used. Electrophoresis and 
dielectrophoresis using alternating current (AC) and iontophoresis using a direct current 
(DC) may be described as the electrically assisted movement of chemicals and molecules 
through the membrane during the application of an electrical potential difference. These 
techniques have been widely used in various medical fields, including topical and 
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systemic drug delivery systems. In particular, the effectiveness of transdermal delivery 
using electrokinetics for the administration of topical anesthesia and analgesia has been 
widely reported reference. Another advantage of electrokinetic methods is the ease of 
interpretation and characterization by Electrochemical Impedance Spectroscopy (EIS) 
based sensors and detection methods.  EP and DEP in combination with EIS can 
effectively trap, manipulate, separate and quantitatively detect particles ranging from 
virus to large DNA strands, to bacteria and mammalian cells in micro fabricated devices.   
Typically interdigitated electrodes and Microelectromechanical systems (MEMS) 
technology are used because they are easy to fabricate, can generate strong electric fields 
with a reasonable voltage, work optimally with micro scale particles, integrate seamlessly 
with micro fluidics, and have analytical electric field solution available for modeling. 
Electrochemically iontophoresis  enhanced transdermal patches are often constructed 
with one active or ―donor‖ electrode and one counter or ―acceptor‖ electrode which are 
placed close to each other and directly against a tissue barrier (stratum corneum).  The 
delivered drug is attached to the donor electrode as a medication soaked sponge or gel.  
In DC iontophoresis, a constant current or voltage is applied between the electrodes to 
promote transport of a drug from the donor electrode to the acceptor electrode through 
the tissue barrier, which is assumed to be a path of least resistance between the two 
electrodes.  In practice this is usually not the case, often resulting in a very low 
percentage efficiency of the drug delivery through the tissue barrier.  In DC iontophoresis 
the rate of drug delivery increases with the current and maintaining a high current (in the 
1 mA range) by applying high DC voltage is desirable.  However, these high currents 
present risks to patients in the clinical setting (a current of 10mA can stop pace maker) 
 44 
 
where the acceptable limit for a DC application is 10 µA.  A number of adverse effects 
have as a result of high applied voltages, including electric burns or erythema;[6] have 
been reported for treatments involving DC iontophoresis. The application of DC-based 
electrokinetics methods has been limited to a period of approximately 15 minutes.  The 
attempt was made to operate at higher frequencies (electrophoretic delivery at ~ 100 kHz) 
where the high current threshold increases to 1 mA.  However, this approach results in 
uncomfortably long treatment times on the order of hours.  Therefore, iontophoresis is 
typically limited to low DC voltages in order to avoid potentially dangerous high 
currents, resulting in a long treatment time (order of hours) required to achieve any 
sizeable drug transport.  However, even for longer treatment times, the amount of 
transported molecules is very small, and therapeutically insufficient in the majority of 
applications. The main goal of this study is to investigate various variables and optimize 
the conditions such as length of treatment and low currents for effective transdermal drug 
delivery of macromolecule e.g. insulin. 
 
4.2 Experimental Materials and Procedures 
4.2.1 Biological tissue membranes and Drug selection 
In this study selected biological tissue membranes- excised pig skin of 1-3mm 
thickness and shedded snake skin of 1 mm thickness were used to investigate 
electrokinetic drug transport. These skins serve as early stage models for transdermal 
drug delivery in humans. Pig skin was stored in a plastic bag in the refrigerator at -10ºC 
and shedded snake skin was stored in a plastic bag at 4ºC. The skins were excised and the 
subcutaneous and fat tissues were removed. The excised skins were composed of stratum 
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corneum, viable epidermis and upper epidermis. Stratus corneum, the outermost layer of 
mammalian epidermis, acts as the main barrier for diffusion of substances through the 
skin. 
In this study, Insulin, Diphenhydramine,  Lidocaine gel, Nimsulide and JCC 76 
with different molecular weights and various polarities were selected as model drug 
compounds. Insulin is a hormone that is central to regulate the energy and glucose 
metabolism in the body. Insulin is a peptide hormone composed of 51 amino acids and 
has a molecular weight of 5808 Da. The interior of insulin contains mostly non-polar 
amino acid side chains, chains e.g. chain to chain bonding with cysteins which are 
nonpolar and hydrophobic while the exterior contains mostly polar amino acid side. 
 
Figure 20: Insulin primary structure 
4.2.2 TA Instruments Dielectric Analyzer DEA 2970 
  Dielectric analysis was performed using TA Instruments DEA 2970. For 
DEA, the sample was placed on a single surface gold ceramic inter-digitated electrode 
and heated to isothermal temperatures. The procedure includes ramp at 5ºC min
-1
 to 37ºC 
and held isothermal for 45 minutes with a flow rate of 50 ml min
-1
 in nitrogen. Shedded 
snake skin, a black snake skin (figure 21) and pig skin (figure 22) were used in this study 
as a barrier for the transport of insulin using an AC electric filed. DEA measures the 
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electrical properties of the drugs used in this study as a function of time, temperature, and 
frequency. Ionic conductivity was then measured as a function of DEA variables to 
obtain permittivity [e‘], dielectric loss [e‘‘] and loss tangent [tan delta=e‘‘/e‘]. 
Permittivity is proportional to the capacitance and measures the number of dipoles. Loss 
factor is proportional to the conductance and represents the energy required to align 
dipoles and move ions by the hopping model (Polaron theory). Ionic conductivity relates 
to the viscosity of the sample because fluidity is identified by the ease with which ionic 
components can migrate through the sample under the applied electric field. 
                                                         
       Figure 21: Shed snake skin                                   Figure 22: Pig skin on DEA sensor    
4.2.3 B-Cell 
The B-Cell (figure 23) was used for initial evaluation of drug transport through 
biological tissue membranes - pig skin (insulin) and concluded with an experimental 
design [4].  The selected biological tissue membranes were positioned with the use of 
several adjusting springs at the bottom of the cell. Then the springs were pressed directly 
against the ―bottom electrode‖ with the stratum corneum facing the electrode to provide a 
realistic model of the 5-electrode setup being firmly placed directly against a skin. The 
biological membranes were sealed properly to avoid cross contamination of the receptor 
and the donor compartments. The receptor compartment is the bottom side of the 
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membrane and the donor compartment is above the membrane containing the original 
drug-containing substance and all the electrodes. The available diffusion area was 
approximately 4 cm
2
.  Approximately 50 mg samples of the drug-containing substance is 
placed on the ―top electrode‖ from the above, with some amount of the substance 
penetrating through the perforation and coming into contact with the biological tissue 
membrane between the bottom Electrodes 4 and 5.  However the majority of the drug-
containing substance remains in the perforation holes, between Electrodes 2 and 3 
comprising the ―bottom electrode‖, and between the Electrode 1 and the plane of the ―top 
electrode‖.  A capping Electrode 1 covers the sample.  All experiments were conducted at 
25
0
C.   
 
Figure 23: B-Cell                                            Figure 24: Interdigitated electrodes 
  
4.2.4 Experimental design and statistical analysis 
 A series of studies was performed to investigate variables which are important for 
transdermal transport of drug and changes in the membrane conductivities as a function 
of voltage amplitudes and frequencies, treatment time, and membrane thickness. This 
type of factorial design identifies the most important parameters affecting drug transport 
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such that the parameters can be optimized for effective transdermal drug transportation. 
The resulting 3³*2 factorial design with two variables at two levels and three variables at 
three levels incorporates a total of 54 studies. 
4.2.5 UV Analysis 
Drug delivery through the membranes was confirmed qualitatively and 
quantitatively by UV spectroscopy. After completion of the drug delivery cycle the 
sample in the receptor cell were collected and quantitatively analyzed by UV-Vis 
spectrometry. The UV-Vis analysis at room temperature was performed and calibration 
curves of known drug concentrations were developed (Insulin at 271.9nm). After each 
experiment three aliquots were taken from each solution and each of these was scanned 
three times. The average of these nine values was used to fit the calibration curve for the 
peak UV absorbance measurements for the residue samples. 
4.3 Results and Discussion 
4.3.1 DSC and DEA Results 
4.3.1.1 DSC 
The heat of crystallization, heat of fusion and heat of vaporization of unbound water are 
334, 334 and 2200 Jg
-1
, respectively. Understanding the role of the solvent (water) on the 
solute drugs can be accomplished by evaluating and comparing the crystallization, fusion, 
and vaporization heats of water in the solutions studied. Next, evaluating the 
crystallization, fusion, and vaporization temperatures we further characterize the solute 
drug in water. In table 2 and 3 the water analysis of each of the drugs in solutions/gel 
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revealed that Insulin, Diphenhydramine, and Lidocaine gel crystallized 10˚C above pure 
water. The melting temperatures were slightly lower than that of pure water and the peak 
melting temperatures were slightly higher than the water for three drugs. The 
vaporization properties of water were similar for insulin and Diphenhydramine, however 
lidocaine gel was significantly difference with a lower amount of water associated to the 
gel. 
Drug (liquid) Tc Tcp ΔHc 
Relative 
ΔHc(%) 
Tm Tmp ΔHf 
Relative 
ΔHf (%) 
Water -34 -30 338 101 -1.0 2.0 373 109 
Insulin -25 -19 315 94 -3.6 3.1 335 100 
Diphenhydramine -25 -18 321 96 -2.1 4.2 345 102 
Lidocaine gel -21 -19 200 60 -4.6 1.4 177 53 
Table 2: Heat of crystallization and heat of fusion by DSC of various drugs 
Drug (liquid) Tv Tvp ΔHv 
Relative 
ΔHv(%) 
Water 99 105 1998 91 
Insulin 102 112 2056 93 
Diphenhydramine 123 131 1998 91 
Lidocaine gel 109 111 1147 52 
Table 3: Heat of vaporization by DSC of various drugs 
A calibrated DSC yielded the melting temperature of Nimesulide at 148-150˚C, 
heat of fusion 54 Jg
-1
, using the TAI DSC 2920 instrument. The literature value for the 
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melting temperature is 143-144˚C.  The crystallization temperature is 104-105˚C and heat 
of crystallization is 46 Jg
-1
. The ratio of the heat of crystallization to that of heat of fusion 
is the amount of the re-crystallized drug, i.e. 86% of the drug Nimesulide re-crystallized 
and by difference 14% is an amorphous form. The melting point of JCC based on the 
DSC results is 180-183˚C and the heat of fusion is 91 Jg-1 (see Figure 25 and 26). 
There is no any recrystallization for JCC and hence it is in amorphous form. 
 
Figure 25: DSC of Nimsulide 
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Figure 26: DSC of JCC 76 
4.3.1.2 DEA 
DEA was used to monitor in vitro delivery of aqueous solutions and solid forms of drugs. 
The Interdigitated single surface electrode was used to sense changes in the ionic 
conductivity as a function of applied frequency at 37
o
C for 45 minutes. Pig skin was 
employed as the animal model to test the drugs through put with frequency. Figure 27 is 
an evaluation of pig skin without any drug applied but the effect of varying frequency 
was measured.  The ionic conductivity (pScm
-1
) is plotted against frequency with a linear 
correlation from log frequency of -1 (10
-1
) to 10
5
 Hz. The response fitted a linear curve fit 
equation of  
log conductivity = 0.668 log frequency + 4.92, R2 = 0.998   (a) 
The insulin test on the electrode produced the next equation see Figure 28. 
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log conductivity = 0.632 log frequency + 4.62,  R2 = 0.996 (b) 
The insulin on pig skin is described in Figure 29 to 31 and equation c and d where the 
curve before the critical frequency of 1.0 Hz is log conductivity = 0.823 log frequency + 
5.73,  R2 = 0.995 (c ) and after the critical frequency log conductivity = 0.195 log 
frequency + 7.29,  R2 = 0.934 (d). 
The interpretation of these curves and equations is that the insulin delivery was enhanced 
as demonstrated by the slope or rate of charge transfer increase from 0.67 (pig skin only) 
to 0.82 (insulin on the pig skin) or the ionic conductivity (related to the concentration of 
the insulin) was enhanced 22%. This template of drug through put is the DEA measure of 
effectiveness of this DEA technique. The slope or rate of ionic conductivity after the 
critical frequency decreased to 0.19 and the curve is flat with minimum variation. This is 
interpreted that the drug was passed through the membrane which will be evaluated by 
UV analysis of the through put fluid described later in this chapter.  
The next aqueous solution with a drug, was with diphenhydramine, and examined 
the same manner. Figure 32 is the overall measure of log ionic conductivity vs. log 
frequency from log frequency from 10
-1
 to 10
5
 Hz, see Figure 33.  Immediately seen is an 
upward movement of the curve at 10 Hz and again at 100 Hz are noted as the critical 
frequencies for this aqueous drug. The general equation curve fit was in Figure 33 
Log conductivity = 0.549 log frequency + 5.85, R2 = 0.901 (e) 
An evaluation of the curve by breaking down the range of response in this case to 10
-1
 to    
10
1
 was in order (frequency range prior the critical frequency). This equation is (f) is 
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 Log conductivity = 0.780 log frequency + 5.80, R2 = 0.994 (f) 
After the critical frequency of 1.0 Hz is viewed in Figure 35 and equation (g) 
 Log conductivity = 0.264 log frequency + 6.89, R2 = 0.323 (g) 
This set of equations and curves implies that the pig skin slope 0.67 increased to 0.78 or a 
16% ionic conductivity enhancement (or a 16% increase in drug through put, which will 
be tested by UV analysis of the fluid beneath the pig skin. The slope after testing was 
0.26 a decrease from 0.78 before the critical frequency. This is also interpreted as the 
drug has passed through the membrane and is depleted from the membrane with a loss of 
drug a lower ionic conductivity.  
Drug 
Mol. Wt. 
(Da) 
% 
Throughput 
by DEA 
W/ Field (V) 
% 
Throughput 
Control 
W/O Field 
(V=0) 
Wavelength (nm) 
UV peak for 
Analysis 
End point 
Conductivity 
(pScm
-1
) 
Nimesulide 
(solid) 
308 22 2.4 290 3.7 x106 
“JCC 76” 
(solid) 
 48 0.0 250 24 x106 
Insulin 
(liquid) 
5808 72 3.2 270 26 x106 
Diphenhydra
mine 
(liquid) 
255 81 17 214 48 x106 
Table: 4  % Through-put and end point conductivity by UV and Dielectric Analysis, 
respectively. 
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Figure 27: DEA of pig skin 
 
Figure 28: DEA of Insulin 
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Figure 29: DEA of insulin behavior on pig skin 
 
Figure 30: DEA of Insulin behavior on pig skin prior to the critical frequency of 100 Hz 
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Figure 31: DEA of Insulin after the critical frequency of 100 Hz 
 
 
Figure 32: DEA of Diphenhydramine as a function of frequency  
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Figure 33: DEA of Diphenhydramine on pig skin 
 
Figure 34: DEA of Diphenhydramine on pig skin prior to the 10 Hz critical frequency 
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Figure 35: DEA of Diphenhydramine on pig skin after critical frequency 
4.3.2 B-Cell Results 
4.3.2.1 Correlation Matrix 
The correlation matrix of investigating variables and outcome measures showed 
strong relationships  |r|= 0.9 to 1.0) between Z, Z‘ and Z‖, indicating the strong 
consistency and validity of the measurements.  A moderately positive relationship (r=0.4) 
is seen between Voltage and Z‖, based on the relationship between Z‖, which is 
proportional to conductivity, and current as defined by Ohm‘s law. Analysis also revealed 
a moderately negative (r = -0.49) relationship between pre- and post-test conductivity and 
low frequency. 
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Table 5: Correlation matrix results 
4.3.2.2 Factor Analysis 
 A factor analysis of the investigating variables and one outcome measure (K) 
found two significant factors (p-value=0.79).  The first factor contains the conductivity 
and voltage variables and the second factor contains the time variable.  The first factor 
explains 22 percent of the variance in the outcome measures and the second factor 
explains 20 percent of the variance, for a total of 42 percent of variance explained by the 
two factors.  This indicates that although the study has captured some of the major 
driving factors of drug transport, other unique variables also contribute to variations in 
outcomes. 
 
 
 
 
                             Table 6: Factor analysis 
Factor 1 Factor 2
K/pS cm-1 0.997
Time/sec 0.996
Voltage/V -0.320
High Freq./Hz
Low Freq./Hz
Factor Loadings
K Time Z' Z'' Z Voltage
High 
Freq.
Low 
Freq.
Pre-Test
Z
Pre-Test
K Delta K
K/pS cm-1 1.0
Time/sec -0.05 1.0
Z'/ohms -0.30 -0.05 1.0
Z''/ohm 0.27 -0.01 -0.94 1.0
Z/ohm -0.30 -0.04 1.00 -0.96 1.0
Voltage/V -0.32 -0.02 -0.26 0.40 -0.29 1.0
High Freq./Hz -0.09 0.02 -0.28 0.22 -0.27 0.03 1.0
Low Freq./Hz -0.08 0.03 -0.17 0.24 -0.19 0.03 -0.03 1.0
Pre-test Z/ohm 0.18 -0.15 0.29 -0.30 0.29 N/A -0.08 -0.61 1.0
Pre-test K/pS cm-1 -0.18 0.17 -0.29 0.30 -0.29 N/A 0.09 0.63 -1.00 1.0
Delta K pS cm-1 0.78 -0.19 -0.18 0.17 -0.18 N/A -0.16 -0.49 0.76 -0.76 1.0
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4.4 Analysis Results 
Increase in conductivity was identified in five of the 54 studies; implying drug transport 
is enhanced by the investigating variables in this study.  The common features of the five 
sets of optimal parameters were a voltage of 1V and a low frequency of 0.1Hz.( figure 
36, 37)  Time was not found to be a significant factor in transport, indicating the process 
is not one of diffusion but is defined by the properties of the applied electric fields.  Drug 
permeation appears to be driven by voltage and low frequency, in combination with an 
appropriate range of high frequencies. 
 
Figure 36:   Conductivity vs. Voltage      Figure 37: Conductivity change vs. Frequency 
4.5 UV Analysis  
Drug throughput into a saline solution below the pig skin membrane was 
measured using a UV-Vis concentration analysis technique in which study sample 
absorbances were fit to a linear calibration curve of standard samples.  Peak absorbance 
was measured at 271.9nm and three aliquots were scanned three times each for a total of 
nine scans for each sample. Throughput ranged from 12 percent to 100 percent, with a 
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mean of 57 percent based on a constant dose of 1mL (100uL) Insulin, with each unit of 
Insulin equal to approximately 0.034mg for a total of 34mg in 1mL.  Transport by weight 
ranged from 4mg (12 percent of 100uL) to 34mg (100 percent of 100uL).  Membrane 
thickness ranged from 0.7mm to 1.8mm with a mean of 1.3mm and has a weak negative 
correlation (r=-0.3) with throughput.  The average standard deviation for the UV-Vis 
scans was 0.016 and the average relative percent error of the absorbance readings was 
1.8, with a range from 0.2 to 5.2. 
 
Figure 38: Average distribution of Insulin frequency Vs. % through put 
4.6 Conclusions 
These results show the proposed series of successive AC fields was capable of 
transporting clinically significant amounts up to 100uL of the macromolecular drug 
Insulin (5,808 daltons) across membranes up to 1.8mm thick in as little as 400 seconds 
given an appropriate range of high and low frequencies coupled with an AC voltage 
signal of 1 to 4 Volts.  Distance to cross the membrane was the most significant factor in 
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determining throughput.  Analysis of pre- and post-test conductivity pointed to five sets 
of parameters with high conductivity change, which may be taken as an indication of 
drug penetration into the membrane separate from drug transported through the 
membrane to the solution below.  In fact, the five studies with high conductivity changes 
had relatively low throughput values, including the lowest value recorded of 12 percent 
throughput.  No localized heating or visible damage to membranes was observed. 
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CHAPTER V 
THERMAL ANALYSIS OF WATER AND MAGNESIUM HYDROXIDE 
CONTENT IN COMMERCIAL PHARMACEUTICAL SUSPENSIONS OF MILK 
OF MAGNESIA 
Abstract 
A standard protocol was developed to determine the water content by thermal 
analysis of Milk of Magnesia (MoM). Differential Scanning Calorimetry (DSC) and 
Thermalgravimetry (TG) were used in a novel manner for examining the physical 
characteristics of the commercial pharmaceutical suspensions. Moisture analyzer and 
oven-dry methods validates the proposed protocol.  
MoM consists primarily of water and magnesium hydroxide (Mg(OH)2). 
Experimental design of the thermal analysis parameters were considered including 
sample size, flowing atmosphere, sample pan and heating rate for both DSC and TG. The 
results established the optimum conditions for minimizing heat and mass transfer effect. 
Sample sizes used were:  (5-15 mg) for DSC and (30-50 mg) for TG. DSC analysis used 
crimped crucibles with a pinhole, which allowed maximum resolution and gave well 
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defined mass (water) loss. TG analysis used a heating rate of 10
o
Cmin
-1
 in an atmosphere 
of nitrogen.   
The heat of crystallization, heat of fusion and heat of vaporization of unbound 
water are 334, 334 and 2257 Jg
-1
, respectively (3). The DSC average water content of 
(MoM) was 80%w for name brand and 89.5%w for generic brand, based on the relative 
crystallization, melting and vaporization heats (Jg
-1
) of distilled water to recently 
purchased (2011) MoM samples. The TG showed a two step process, loosing water at 80-
135
o
C for unbound water and bound water (MgO.H2O) at 376-404
o
C, yielding a total 
average water loss of 91.9% for name brand and 90.7% for generic brand by mass. The 
difference between the high temperature TG and the lower temperature DSC can be 
attributed for the decomposition of magnesium hydroxide or MgO.H2O. Therefore in 
performing this new approach to water analysis heating to a high temperature 
decomposed the magnesium hydroxide residue. It is our considered opinion that the DSC 
method is more accurate than the TG protocol for unbound water. 
Key Words: Milk of Magnesia (MoM), Differential Scanning Calorimetry (DSC), 
Thermal Gravimerty (TG), Unbound water and Bound water 
 
 68 
 
5.1 Introduction 
In general, water can be organized by phases of matter: liquid, solid and gas. The 
liquid phase is the most common among all the water phases on the surface of the earth 
and this phase is noted as ―water‖. The solid phase of water is a physically hard structure, 
which is commonly known as ice. The gas phase of water is recognized as vapor or the 
―vapor phase‖ of water.  The physical chemistry of water is denoted as one molecule of 
water where two hydrogen atoms are covalently bonded to a single oxygen atom (2). 
Liquid water has no taste or odor and at normal atmospheric temperature and pressure 
water is colorless, however it can have a very light blue hue. Ice is colorless, water vapor 
or steam cannot be seen as a gas.  At standard conditions, 25˚C and pressure 1atm water 
is a liquid. The water molecule has a net positive charge on the hydrogen atoms and a net 
negative charge on the oxygen atom. The net result is that each water molecule has a 
dipole moment. Water is a polar liquid that can form a hydronium ion (H3O
+
) and is 
interactive with hydroxide ion (OH
-
). 
2 H2O (l)  H3O
+ (aq) + OH− (aq) 
 The heat of vaporization, (ΔHv), is the energy to change a given quantity of water 
into its gas phase at the standard temperature and pressure. Heat of vaporization for water 
is 2257 Jg
-1
. The heat of fusion (ΔHf) is the result of the change in the phase of water 
from solid to liquid which occurs at the melting temperature (Tm)). Heat of fusion for 
water is 334 Jg
-1
. The heat of crystallization (ΔHc) is the result of the change in the phase 
of water from liquid to a solid which occurs at the crystallization temperature (Tc)). Heat 
of crystallization for water is 334 Jg
-1
[3]. 
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  The following is a summary from W.J. Sichina paper ―Characterization of Water 
of Hydration of Pharmaceuticals Using the DSC‖. He developed a test to characterize the 
properties associated with the waters in a pharmaceutical material. The method includes 
automated sample pan puncturing accessory for the study of free and bound waters in 
pharmaceuticals. An additional protocol for determining hydrated pharmaceuticals 
materials is DSC.  Sichina‘s DSC protocol includes a thermal program: heat from room 
temperature at 10˚Cmin-1, sample mass approximately 4 mg, sample pan 30 µl aluminum 
pan with a hole, and purge gas nitrogen [2]. 
Milk of Magnesia is a suspension of magnesium hydroxide Mg(OH)2 in water. It 
is widely used as an antacid to neutralize stomach acid and laxatives. Low solubility of 
Mg(OH)2   in water makes it  a weak base and considered as a strong electrolyte. The 
United States Pharmacopeia states that single strength Milk of Magnesia should contain 
not less than 90.0 % and not more than 115.0% of the labeled amount of 80 mg of 
Mg(OH)2mL
-1
.  It is commercially produced by the precipitation of magnesium 
hydroxide paste from seawater. The paste can have varying degrees of viscosity, which 
determines whether a suspending agent is required or not.  Water, whose melting 
/crystallization temperature and enthalpy are not significantly different from those of 
normal (bulk) water, is called free water or freezing water or unbound water.  Those 
water species exhibiting large differences in transition enthalpies and temperatures, or 
those for which no phase transition can be observed calorimetrically are referred to as 
bound water.  
The purpose of these experiments is to find the best analytical method to 
determine bound, unbound water and water activity.  Oven-dry and moisture analyzer 
 70 
 
methods are traditional methods, which are used in this experiment as controls. They are 
used to determine the total water lost from the test samples. Since both traditional 
methods can only determine the total amount of water lost, these methods cannot be used 
to determine bound, unbound water and water activity.  
TG rapidly measures changes in mass as a sample is heated and is eventually 
vaporized. This can be used to create a water loss profile that can show the different 
temperature ranges in which water and other components of a sample vaporize. DSC 
analyzes the phase changes in matter and can also be used to determine a water loss 
profile. Both methods can be used to determine the amounts of bound and unbound water 
and from which can be used to determine the total amount of water lost in a sample. This 
will be compared to the traditional controls to determine if the novel methods can be 
accurately used to determine bound, unbound, and total water in a sample of milk of 
magnesia. 
5.2 Experimental Methods 
The laxatives used in the study were a brand name milk of magnesia and a generic brand 
milk of magnesia. Each product was tested for water content using two conventional 
methods: 110°C oven, and moisture analyzer and two novel methods: Differential 
Scanning Calorimetry and Thermalgravimetry.  
5.2.1 110°C Oven Method 
This method used small aluminum pans, a vacuum oven set to 110°C, and a desiccator. 
First, the aluminum pans were analytically weighed and recorded to 3 decimal places. 
Next, two samples of each product were analytically weighed from 1.5-2.0 grams onto 
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separate pre-weighed pans to 3 decimal places and recorded. Then the pans were placed 
into the vacuum oven. The oven used was a Fisher Scientific Isotemp® vacuum oven 
model 282A (figure 39). Pans and samples were left in the oven for 3 hours at 15 kPa 
vacuum. After 3 hours, the pans were removed from the oven and immediately placed 
into desiccator under vacuum for 1 hour. After one hour, the pans were removed from the 
desiccators and were analytically weighed and recorded to 3 decimal places.  
                       
Figure 39: Fisher Scientific Isotemp® 282A 
5.2.2 Moisture Analyzer Method 
Samples of each product were analyzed for moisture content using the Lab wave 9000 
Moisture Analyzer (figure 40). The moisture analyzer uses an analytical balance inside of 
a microwave oven (figure 41), which dries the sample, while recording a change in mass. 
At the end of the test the percent moisture of the sample is automatically calculated. First, 
two absorbent pads are placed on the analytical balance inside the moisture analyzer and 
the balance is tared. Next, 1.0-1.5 grams of sample is placed in between the absorbent 
pads. Then the moisture analyzer is activated, using 80% power. The sequence is 
completed when the moisture analyzer no longer records a change in mass. The 
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instrument then displays the percent moisture, percent solids, and the amount of time it 
took to complete the analysis.  
 
                            Figure 40: Lab wave 9000                 Figure 41: Inside 
 
5.2.3 Thermogravimetry Method (TG) 
A TA Instruments Hi-Res Thermalgravimetric Analyzer Model 2950 (figure 42) was 
used to measure bound and unbound water in milk of magnesia samples. The samples 
were prepared by placing one drop of material on to a pre-tared platinum TG pan. The 
pan was placed onto the auto-loading mechanism of the TG analyzer and an automated 
loading sequence was initiated. The sample is placed into a furnace which heats the 
sample, while measuring the mass of the sample every 0.5 second. The TG experimental 
conditions were: Ramp 10°C per minute to 500°C in nitrogen. 30-50 mg of sample was 
used in each run.  
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                                            Figure 42: Thermalgravimetric Analyzer Model 2950 
 
5.2.4 Differential Scanning Calorimetry Method (DSC) 
The Mettler DSC 823
e
 20 instrument (figure 43) was used to measure the heat flow 
properties of the milk of magnesia samples which involve exothermic or endothermic 
processes as a function of time and temperature. Samples were placed in solid fat index 
(SFI)  aluminum pans with sampling size ranging from 5 mg to 15 mg, covered with a lid 
and were sealed. The samples were cooled from 25 to -50
°
C and then heated to 120°C at 
5˚Cmin-1 heating rate with nitrogen gas purge of 50 mL.min-1. Closed pans were used in 
this study. The DSC scan provided  data of the following thermal properties: Heat of 
fusion  ∆Hf), melting temperature (Tm), peak melt temperature (Tmp), heat of 
crystallization  ∆Hc), crystallization temperature (Tc), peak crystallization temperature 
(Tcp), heat of vaporization ∆Hv), vaporization temperature(Tv) and peak vaporization 
temperature(Tvp). 
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                               Figure 43: Mettler Toledo DSC 
 
5.3 Results and Discussion 
The results of % water from the 110°C pan method are shown in table 7: 
Source drug suspension Sample Water Average  SDEV 
Milk of Magnesia (Name Brand) 1 91.8% 91.8% 0.0 
 
2 91.7% 
  
Milk of Magnesia (Generic Brand) 1 90.6% 90.%6 0.1 
 
2 90.7% 
  
Table 7: Results of % water from pan method 
The results were obtained by subtracting the mass of the pan and sample after testing, 
from the initial mass of the pan. The difference was the amount of solids left in the pan. 
From there, the mass of the material left in the pan was subtracted from the initial mass of 
the sample. The data shows that the amount of water in the commercial brand of milk of 
magnesia to be 91.8% and the generic brand of milk of magnesia was 90.6%.  The 
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moisture analyzer results were virtually identical to the results obtained from the 110° C 
pan method as seen in Table 8.  
 Total Water (Oven)*  Total Water* (Analyzer) 
MoM (Name Brand) 91.8% 91.9% 
MoM (Generic Brand) 90.6% 90.8% 
*Average values   
 Table 8: Comparison of two conventional methods for water content in milk of magnesia 
TG data was analyzed using Universal Analysis 2000, by TA Instruments, version 4.4A. 
The data was plotted and analyzed using the first derivative of the percent (%) mass loss 
versus temperature in °C. From there, each peak was identified and the percent material 
loss was calculated. Also identified were the initial and end points at which mass loss 
began and ended. All remaining material in the sample was calculated as percent residue. 
The results are shown in figures 44 and 45.  
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              Figure 44 : TG analysis for name brand 
 
                        Figure 45:  TG analysis for generic brand 
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In comparison to the conventional methods, TG analysis showed both bound and 
unbound water.  Water vaporization results are shown in table 9. The unbound water 
vaporized between 80°C and 119°C in the name brand MoM. The unbound water in 
generic brand MoM vaporized between 91° and 135°C. The bound water in the name 
brand MoM vaporized between 376° and 398°C and between 374° and 404°C in the 
generic brand MoM.                
 
 Unbound Water Bound Water Total Water 
MoM (Name Brand) 88.0% 2.2% 90.2% 
MoM (Generic Brand) 88.3% 2.4% 90.7% 
                    Table 9: % of unbound water and bound water for test samples by TG 
DSC results are summarized in the Figures 46, 47 and 48 as well as tables 10 and 
11. The free water concentrations were determined based on the cool and heat DSC 
curves. The heat of crystallization, ΔHc (from the cooling curve) and the heat of fusion, 
ΔHf (heating curve after crystallization) were calculated for pure water and the 
commercial suspensions of milk of magnesia produced by a name brand and a generic 
pharmaceutical contract packager. The free or unbound water are the focus of this study 
and by difference the amount of water relative to the ―pure‖ water. Assuming a two 
component suspension of water and magnesium hydroxide (Mg(OH)2 suspended in the 
water), various samplings of the commercial suspensions were evaluated by the DSC 
curves. The average, standard deviation and percent relative error were calculated from 
the ΔHc and ΔHf measured and are reported in table 10. The standard deviation was ± 17 
to ± 22 and the % relative error was 5.3 to 7.6% for the heat measurements. The heat of 
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vaporization was recorded during the DSC run but due to baseline variations and 
sampling techniques were not used for the calculation of the water content.  
 
 Figure 46: DSC analysis for distilled water 
 
 
 Figure 47: DSC analysis for name brand MoM 
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 Figure 48: DSC Analysis of Generic brand 
 
Drug (liquid) 
Average 
ΔHc/Jg
-1
 
Standard 
deviation/± 
%  
Relative 
error 
Average 
ΔHf/Jg
-1
 
Standard 
deviation/± 
% 
Relative 
error 
Distilled water 338 19 5.5 373 20 5.3 
Milk of Magnesia (Name Brand) 276 17 6.1 291 18 6.2 
Milk of Magnesia (Generic Brand) 312 18 5.4 326 22 7.6 
*All values Hc and Hf are based on three samplings 
Table 10: Average, standard deviation and % relative error of ΔHc and ΔHf  
 
 
 
 
 
 80 
 
Drug (liquid) 
Tc 
°C 
Tcp 
°C 
ΔHc 
Jg
-1
 
Relative 
ΔHc% 
Tm 
°C 
Tmp 
°C 
ΔHf 
Jg
-1
 
Relative 
ΔHf% 
Average 
of ΔHc 
and 
ΔHf 
Distilled water -18 -14 338 100 0 3.0 373 100 100 
Milk of Magnesia (Name Brand) -17 -13 276 82 
-
1.2 
2.0 291 78 80 
Milk of Magnesia (Generic Brand) -17 -12 312 92 
-
1.3 
2.0 326 87 89.5 
Table 11: Relative ΔHc , ΔHf and average of ΔHc and ΔHf 
The final summary of the DSC analysis includes: the temperature profile of the free or 
unbound water, its water content relative to the ΔHf and ΔHc and the average result of the 
water by both analytical techniques, see table 12. The Milk of Magnesia, name brand and 
generic brand was 80.0% and 89.5%, respectively by DSC. Therefore, there appears to be 
a 10% variation between the two MoM commercial samples. 
Source Suspension 
Oven 
110˚C 
Moisture 
Analyzer 
 TG 
Mettler 
DSC 
Viscocity* 
mPa∙s 
Milk of magnesia (Name 
brand) 
91.8% 91.9% 90.2% 80.0% 1585 
Milk of 
Magnesia(Generic Brand) 
90.6% 90.8% 90.7% 89.% 2980 
*Brookfield DV II+ Viscometer (#3 RVT spindle at 20rpm) 
Table 12: Percent of water content from all the techniques and viscosity for test samples 
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An overview of the water content by four analytical techniques is reported in table 12. 
The water content for the Oven Test at 110˚C, the Moisture analyzer, TG and DSC for:    
Name Brand was 91.8, 91.9, 90.2 and 80.0%w, respectively.  
Generic Brand was of 90.6. 90.8, 90.7 and 89.5%w, respectively  
The differences between the brand and generic were the same for the oven, moisture 
analyzer and TG methods.  There was a repeatable difference based on the DSC analysis 
of 10% more water in the generic sample. Further, there was a sizable viscosity 
difference of 88% between the brand and generic. The generic had more water and a 
higher viscosity. The latter may be due to the additional additives denoted by 20 mg 
calcium and 2 mg sodium in the generic product. The calculation of water activity was 
developed to account for the intensity with which water associates with various non-
aqueous constituents, e.g. MOM. It is a measure of the energy status of the water in a 
system (10, 11, and 12). It is defined as the vapor pressure of a liquid divided by that of 
pure water at the same temperature, yielding a value of one or 100%. It is our 
interpretation that the difference noted in the DSC analysis is due to water activity and 
can be uniquely evaluated by DSC. 
5.4 Conclusions 
The conventional methods of water analysis, oven and moisture analyzer provided total 
water. TG is used to determine the bound and unbound water in MoM. DSC uniquely 
discovered 10% more water in the generic probably due to water activity. The differences 
in alkali metal content can be associated with the DSC water activity or may be related to 
the enhanced viscosity of the generic brand. 
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CHAPTER VI 
AC ELECTROKINETIC PLATFORM FOR IONTOPHORETIC 
TRANSDERMAL DRUG DELIVERY 
Abstract 
Iontophoretic and electroporation transdermal delivery modes of ionic drugs have been 
utilized in a number of clinical and biomedical devices. However, applications of these 
methods have been found challenging for the delivery of many non polar and high 
molecular weight clinically important drugs. The main goal of the present study is to 
investigate whether transdermal transport of non polar macromolecular drugs such as 
insulin and terbinafine can be safely enhanced as a result of their polarization and 
activation by AC electrokinetic forces. An in vitro delivery system was developed to 
simulate a clinical application, where transdermal non invasive delivery of medication 
through a biological membrane is motivated by a combination of AC electrokinetic and 
AC iontophoresis protocols generated on a device located external to the membrane. The 
developed method resulted in an average transdermal delivery of 57% of insulin and 39% 
of terbinafine during several minutes long delivery cycle, which is at least an order of 
magnitude improvement over the results reported for these drugs in the literature for 
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various passive and active transdermal delivery protocols. For the proposed drug delivery 
model quantification of the amounts of transported drugs and their relationship to 
experimental parameters, such as AC voltage amplitude and frequency, treatment time, 
and membrane thickness were investigated. Experimental results validated a 
computational model simulating the effects of major electrokinetic forces on drug particle 
in non uniform AC electric field. The presented transdermal approach overcomes many 
limitations of existing drug delivery technologies, providing efficient, regulated, 
localized, non invasive and safe delivery method for high molecular weight non polar 
macromolecules such as insulin. 
Key words 
Electrokinetics, Iontophoresis, Impedance, Insulin, Terbinafine, Transdermal 
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6.1 Introduction 
Over the past decade non invasive transdermal drug delivery has become increasingly 
common. Transdermal drug delivery offers many benefits over oral, IV and injection 
therapies, in which procedures often result in adverse clinical side effects, and/or 
clinically sufficient quantities of the active ingredient do not reach the intended organ 
either fast enough or in high enough concentrations. That typically occurs because of the 
partial medication degradation when passing through various physiological environments 
(e.g. low pH values in the stomach), slow or incomplete absorption, or adverse affect on 
healthy organs and tissues. Transdermal procedures provide improved bioavailability and 
pharmokinetics, offering localized non invasive treatment, prolonged controlled release, 
and increased patient compliance. However, only a limited number of drug candidates 
have been successfully developed into suitable transdermal formulations because of the 
formidable dermal barriers such as stratum corneum outer layer of the skin. Further 
advancements in transdermal methods are required, especially for delivery of high 
molecular weight non ionic drugs [1]. Most of contemporary transdermal products are 
based on passive diffusion of a drug through skin over time. More recently, ―active‖ 
iontophoresis drug delivery methods that may transfer a drug at a controlled rate have 
been developed and commercialized as transdermal patches [1-9]. Transdermal 
iontophoresis is a technology that enhances drug transport across the skin barrier with the 
assistance of an electric field. The mechanisms of transdermal iontophoresis include 
electrophoresis (EP) [10-12], electroosmosis (EO) [13, 14] and electroporation [15, 16]. 
Direct current (DC) iontophoresis is the most common type. Electroporation and 
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iontophoresis skin treatment have been shown to be effective through induced 
disorganization of lipid bylayers of stratum corneum and increase in skin hydration [5-7]. 
High current intensity (in case of electroporation) or extensive treatment times (in 
case of DC iontophoresis) can potentially lead to electrochemical burns, pain, and skin 
irritation [5, 6]. It has been suggested that AC iontophoresis can eliminate these negative 
side effects [17, 18]. Although high amplitude AC field applied in frequencies exceeding 
10 Hz may provide less flux enhancement than DC field, significant flux enhancement 
has been observed during AC iontophoresis at constant current or constant voltage [17-
21]. It has been shown that the AC electric field reduces skin electrical resistance by the 
mechanism of electroporation similar to that which occurs during DC. This 
electroporation effect has been found to dramatically increase with the AC voltage 
amplitude [20]. The flux enhancements due to EP and EO have been shown to be 
dependent on the AC voltage and AC frequency range [18]. 
Iontophoretic methods, however, were shown to be only of a very limited 
efficiency in transdermal transport of many clinically important non polar and high 
molecular weight drugs (such as insulin and terbinafine) [2]. Even for longer treatment 
times transdermal delivery of conventional insulin in humans has been largely 
unsuccessful presumably due to its weak ionization and partial polymerization, although 
a delivery of modified, strongly ionized monomeric form of insulin was successful in 
animals [22]. Inducing a temporary polarization on otherwise non polar macromolecules 
may result in better overall compliance with iontophoretic transdermal transport. 
Recent years have witnessed significant advances in the field of electrokinetic 
manipulation of various biological species. Electrokinetic forces, such as EP EO, and 
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dielectrophoresis (DEP) have been widely used for manipulation, detection and 
separation of nano- and microparticles, such as proteins, bacteria, DNA, and blood cells 
[23-27]. Magnitude of forces can range widely, depending on particle size, position away 
from electrode and characteristic dimension of the electrode. A useful approach to 
manipulate particles at the microscale is to use electric fields to apply long range EP 
forces to charged particles, or induce dipoles and separate particles using a relatively 
short-range DEP. Electrokinetics has shown to be ideal for the manipulation of particles 
with sizes down to 20 nm, when small electrode channels (100 nm) and high voltages 
(~10 V) are utilized [24]. Electric fields work optimally with microscale particles and 
MEMS devices, integrating seamlessly with microfluidics and electrochemical sensors 
[27]. 
Relatively few systematic studies of AC motivated drug delivery methods in 
clinical settings, in particular those of higher molecular weight drugs, have been 
performed [28-30]. AC electrokinetics with its ability to vary effects of different forces 
on a particle may potentially become a highly effective method of drug delivery through 
biological membranes. However, the efficiency of drug delivery has to be optimized 
while making sure that currents through tissue membranes are kept low, treatment times 
are short, and the risk of localized electrical heating and other potential side effects are 
controlled. The main goal of this study was to investigate whether transdermal transport 
of two macromolecular drugs — insulin and terbinafine could be safely enhanced using 
the principles of AC electrokinetics. 
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6.2 Materials and methods 
6.2.1 Materials 
Terbinafine hydrochloride (Lamisil) is a synthetic non polar antifungal drug with a 
molecular weight of 291.43 g/mol and molecular size of ~0.78 nm. For terbinafine 
delivery studies Lamisil cream formulation (1% terbinafine, or 10 g/L), widely available 
over the counter, was selected. Insulin is a high molecular weight (5808 Da or ~9500 
g/mol) peptide hormone with the interior composed of non polar amino acid side chains, 
while the exterior contains polar amino acid side chains. The molecular dipole moment of 
a monomer insulin molecule is a fairly sizeable 72 D at 25 °C [31]. The molecule has a 
size of ~2.8 nm but larger aggregates may grow in time in aqueous solutions. For 
transdermal insulin delivery studies, Humalog® N (Eli Lilly, Indianapolis, IN) was 
chosen as a standard rapid acting insulin formulation in wide clinical use. Humalog® N 
is an isophane suspension of human insulin in a 10 mL vial of 1000 units, or 
approximately 4.17 g/L. Viscosity (0.001 Pa s), thermal conductivity (0.6 J/m sec K), 
permittivity (80) and electrical conductivity  10 μSm/m) of background mediawere taken 
to be approximately equal to those of water at roomtemperature. For insulin and 
terbinafine the values for permittivity (55 and 20, respectively) and conductivity (500 
μSm/m and 100 μSm/m, respectively) were estimated from the impedance measurements, 
in agreement with the literature data on these drugs and their amino acid components 
[31]. Insulin and terbinafine conductivity values were confirmed by the measurements of 
the particle seizes and the zeta potentials (−20.1±1.3 mV and −6.6± 1 mV, respectively) 
at physiological pH 7.4 (Brookhaven Zeta PALS,Brookhaven Instruments, Holtsville, 
NY).  
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Excised pig skin and cow hoof were selected to serve as models of human skin 
and nail tissues, respectively [32, 33]. Animal tissues are readily obtainable in sufficient 
quantities to allow conducting properly controlled and reproducible multiple experiments. 
Pig skin samples with thickness ranging from 0.1 cm to 0.2 cm were obtained from the 
breast region of adult Yucatan pigs because of the lower density of hair follicles in this 
area, and were stored in sealed plastic bags in a refrigerator at −80 °C before use. The 
surfaces of the skins were cleansed with a mild skin-cleaning gel normally used for 
bioelectrical measurements and residual hair was removed with clippers. The epidermis 
and upper dermis were removed with a dermatome. 0.1 cm thick (±5%) cow hoofs were 
washed in the donor compartment buffer, dried, and stored in desiccator until use. The 
surface areas of both membranes were cut to approximately 2 cm×2 cm. 
The membranes were mounted between two side-by-side diffusion chambers 
(diffusion surface area around 4 cm2 and cell volume of 4 mL) with the stratum corneum 
side facing the donor chamber. The biological membranes were sealed properly to avoid 
cross contamination of the ―receiver‖ and the ―donor‖ chambers. Approximately 500 μg 
samples of Lamisil cream or 500 μL of Humalog® solution were placed in the donor 
chamber. The receiver chamber was filled with phosphate buffered saline (PBS), 
containing 1.5% bovine serum albumin (BSA) (pH 7.4) or absorbent cloth was used to 
capture transported substance and overnight. The pH of the receiver solution was checked 
in a few occasions and was found to be essentially the same during the experiments. The 
receiver chamber was thermoregulated at 32±1 °C (skin temperature in vivo) in heated 
bath system (Lauda, Lauda-Königshofen, Germany). Both donor and receiver chamber 
solutions were replaced after each experiment. The experimental system composed of the 
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donor and the receiver chambers, the membranes, and the iontophoretic electrodes, were 
housed in a rectangular (2 cm×2 cm×2 cm) polyamide cube designed and manufactured 
in-house (Figure 49A). The system employed three separate voltage and current carrying 
electrodes — a counter electrode prepared out of a 0.1 cm thick stainless steel 316 metal 
film (Electrode 1), and two interdigitated iontophoretic electrodes (Electrode 2 and 
Electrode 3) placed directly on top of the stratum corneum layer of the membranes in the 
donor chamber. The counter Electrode 1 with a surface area of 4 cm2 was custom fit to 
the cell exactly and was separated from the ―top electrode‖ plane by 300 μm thick 
TeflonR spacers. Electrodes 2 and 3 were machined out of stainless steel 316 into sets of 
interdigitated comb-shaped fingers with a thickness and height of 0.05 cm, and the length 
of 1.8 cm. 
 
 
Figure 49: Cross-section (A) and top view with counter electrode removed (B) of the 
experimental set-up: 1 — counter Electrode 1; 2 — Teflon spacer; 3 — medication; 4 — comb-
shaped Electrodes 2 and 3; 5 — air channels through Electrodes 2–3; 6 — biological tissue 
membrane; 7 — spring supports; 8 — B-Cell housing; 9 — electrical connectors to Electrodes 1–
3; 10 — receiver solution or absorbent cloth; 11 — temperature probe. 
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 The gaps between the adjacent electrode fingers were fixed at 20 μm. Resistance of the 
electrode array in the background solution was measured at 22 k Ohm. The resulting 
plane composed of Electrodes 2 and 3 allows transport of compounds at the donor 
chamber in the direction perpendicular to the plane toward the stratum corneum interface, 
providing a realistic model of a transdermal drug delivery with the electrical field being 
applied on a medication located externally to the membrane. The cell was equipped with 
a temperature probe with an accuracy ±1 °C to monitor possible Joule heating effects. 
6.2.2 Experimental methods 
Impedance/Dielectric Analyzer (Novocontrol GmbH, Hundsangen Germany) using ZG4 
cell adapter in a two-electrode arrangement was employed to supply the excitation signals 
to the electrodes; to determine the system impedance responses as a function of time, AC 
voltage and frequency; and to examine impedance changes in the membranes after the 
experiments. The impedance frequency scans were performed between 0.1 and 100,000 
Hz with AC voltage amplitudes (peak-to-baseline) between 100 mV and 10 V and no DC 
offset. This analysis was used to evaluate impedance mismatches (Clausius–Mossotti 
polarization factor) between the media and the drug molecules as a function of applied 
AC frequencies [34]. In the developed drug delivery model, the intention was to subject 
the drugs to ―polarization‖ AC electric perturbation with a purpose of invoking a 
temporary polarization on the particles, followed by a ―motivation‖ AC signal to 
facilitate transport of the polarized drug through the membrane [5,6]. With that in mind, 
two successive AC electric fields were created between counter Electrode 1 and 
interdigitated Electrodes 2 and 3 ―shortened‖ together  ―Circuit 1‖), and separated 
interdigitated Electrodes 2 and 3  ―Circuit 2‖). In this delivery model the purpose of 
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Circuit 1 is to invoke polarization and electrokinetic transport on the drug particles by 
operating at polarization frequency determined from the Clausius–Mossotti polarization 
factor analysis. Circuit 2 operates in AC iontophoretic mode influencing the particles 
transdermal transport and reducing the skin resistance by electroporation mechanism 
[18]. A switchboard designed ―in-house‖ transferred excitation signals between Circuits 1 
and 2 with under millisecond time delay. In addition, 1200 s long control experiments 
were performed, both with the drugs present at the donor chamber without any external 
electrical excitations, and with Circuit 2 used to influence the drug delivery in a constant 
current (0.2 mA) iontophoretic mode, similar to currents used in commercially available 
iontophoretic devices. In the control experiments polarization of the drug particles 
utilizing Circuit 1 was not performed. 
In order to verify the effectiveness of the drug delivery through the membranes, the pig 
skin and cow hoof samples were visually analyzed after each test for appearance of 
residue on the receiver chamber side, and for the changes in their electrical impedance 
[5–9]. The electrical impedance of the membranes was determined by the electric current 
and voltage drop across the samples according to Ohm's law. The studies also included 
temperature readings of the skin surface before, during and after each experimental study 
to determine the effects of electrical heating. Drug throughput into the receiver chamber 
was quantified using a UV–Vis concentration analysis technique in which study sample 
absorbencies were fit to a linear calibration curve of standard samples. The UV–Vis 
analysis (Varian Cary 300, Absorbance range 2–4 Abs; precision: ±0.002 Abs) at room 
temperature was performed and calibration curves of known drug concentrations (5 
samples) were developed (terbinafine at 222 nm and insulin at 271.9 nm). After each 
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transdermal experiment, the receiver solution samples were collected. Three separate 
aliquots were taken from each solution; each of the three aliquots was scanned three 
times. The average of these nine values was used to fit the calibration curve for the peak 
UV absorbance measurements for the residue samples. The average standard deviation 
for the UV–Vis scans for Lamisil and Humalog® studies was 0.016 and the average 
relative error of the absorbance readings was 1.8%, with a range from 0.2% to 5.2%. 
Lamisil has a number of surfactants that can potentially interfere with UV–Vis 
detection of terbinafine. Therefore, terbinafine transport was separately confirmed by 
GC-MS (Varian 3900/Saturn 2000), in which the components of a sample are separated 
and measured by their molecular mass and time of detection. The drug residue collected 
from the absorbent cloths was placed in methyline chloride or hexane solvents (each 
residue was dissolved in 10 mL solution and stored in30 mL amber bottles) before the 
GC-MS analysis. The intensity of the peaks could then be used to calculate the amount of 
terbinafine based on the standard samples. 
6.2.3 Experimental design and statistical analysis 
A series of studies was performed to investigate the transdermal transport and 
changes in the membranes' conductivities as a function of AC voltage amplitudes and 
frequencies, treatment time, and membrane thickness. This type of factorial design 
identifies the most important parameters affecting drug transport and pinpoints optimal 
ranges for those parameters. The resulting 5
3
*2
2
 factorial design with two variables at 
two levels and five variables at three levels for insulin, and 4
3
*2
2
 for terbinafine is 
summarized in table 13. 
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Levels 
 
Circuit 1 
 
Circuit 2 Membrane 
Thickness 
mm 
Time (sec) 
AC voltage 
amplitude 
(V) 
Frequency 
(Hz) 
Time 
(sec) 
AC voltage 
amplitude 
(V) 
Frequency 
(Hz) 
1 100 0.1 1.0 100 0.1 0.1 1.0 
2 1200 1.0 100 1200 1.0 1.0 1.5 
3  10 10000  10 100 2.0 
 
Table 13: Factorial design for terbinafine and insulin. 
 
This factorial design incorporates a total of 500 studies for insulin and 256 studies 
for terbinafine with the data analysis performed using StatGraphics OnlineR (StatPoint 
Technologies, Warrenton, VA) software. For each study two controls were incorporated, 
one without any electrical excitation; and one applying constant 0.2 mA current DC 
signal for 1200 s. A broader study of the effects of other input control parameters, such as 
geometry of the device; thickness, type and condition of the membrane; initial amounts 
and type of drugs; and localized external heating for regulating transdermal transport 
through animal and human skin model is being developed at that time. 
 
6.3 Results and Discussion 
6.3.1 Simulation of the AC electrokinetic forces 
Before conducting an experimental evaluation of the transdermal transport concept, a 
computational model was developed taking into consideration a variety of polarization 
and electrokinetic forces influencing drug particles in external non uniform AC electric 
field created by the asymmetrical Electrodes 2 and 3 and counter Electrode 1. The effects 
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of EP, EO, drag, and Brownian forces can be estimated from Smoluchowski, Helmholtz–
Smoluchowski, Stokes, and Brown equations for small particles, respectively [24–27]. 
Joule heating temperature increase resulting from the application of external electric field 
can be estimated [25,26] for a fluid with conductivity σM and thermal conductivity k as 
ΔT=σMERMS 2 /k, where ERMS is the root mean square value of the AC electric field 
[24]. An applied electric field and resulting localized Joule heating also result in 
temperature gradient in the medium and spatial variations in the conductivity, 
permittivity, viscosity, and density of the solution, creating inhomogeneous coulomb and 
dielectric body forces in a fluid. This phenomenon is known as the ―electrothermal 
effect‖ and can induce microscale fluid motion, thereby non invasively stirring the fluid 
at the microscale. An order of magnitude estimation of the electrothermal flow was 
provided [25, 26] as FELTHERM=ERMS 2  1/ ε)  dε/dT) / 2. The effect of the 
gravitational force was assumed to be negligible. 
Manipulation of biological species by DEP is one of the most broadly applied 
microfluidic sorting methods. A dipole movement is induced on the biological particles 
when they enter non uniform AC field. Polarized particles incur AC frequency-dependent 
DEP force that is unique to the particle type and size. The time-averaged DEP force 
acting on a particle with radius a is estimated asFDEP= 2πa3εMε0RE[K]gradERMS 2 . 
The real part of the Clausius–Mossotti factor RE[K]=RE[ εP * −εM * )/ εP * +2εM * )] 
represents the frequency-dependent mismatch in complex dielectric properties of the 
media  εM * ) and the particles  εP * ). Variations in this factor give rise to a DEP force 
that is frequency dependent and unique for a particle type. The DEP force can induce 
selective particle movement to regions of high or low potential field, depending on the 
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polarizability of the particles compared with that of the suspending media, and resulting 
positive or negative value of the Clausius–Mossotti factor. ―Positive‖ DEP force directs 
the particles toward the high potential region of the electric field, while a ―negative‖ DEP 
propels the particles in the direction of decreasing field strength. The DEP mobility of a 
particle scales directly with its surface area, so that to manipulate small particles larger 
electric field gradients are required [34]. Thus by using a mismatch in conductivity and 
permittivity values of medium and particles, submicron non polar particles can be 
elegantly manipulated on planar and 3D interdigitated electrodes in steady pool and 
continuous flow. 
A simulation of the electric field distribution between asymmetrical electrodes 
was modeled using ANSYS Multiphysics (Canonsburg, PA), a finite element software 
package. A two-dimensional model was sufficient to describe the electric fields created 
by Electrodes 1, 2 and 3. The result of the simulation shows that the electric field 
distribution is the strongest and the electric field gradient is at its maximum in the 
vicinity of the interdigitated Electrodes 2 and 3; particles which undergo positive DEP 
should be attracted to those regions. These estimates were conducted for particles located 
10 μm from the plane of Electrodes 2 and 3. Figure 50 shows the frequency dependence 
of the Clausius–Mossotti polarization factor for insulin and terbinafine. It can be seen that 
both insulin and terbinafine experience positive DEP force at frequencies under 1 MHz, 
allowing to polarize and attract both drugs toward the region of higher field strength at 
the edges and in the gap between Electrodes 2 and 3. 
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Figure 50:  AC frequency dependence for Clausius–Mossotti polarization factor for: insulin (■) 
and terbinafine (▲). 
 
In agreement with the literature data for nanometer sized particles and ~μm-sized 
characteristic dimensions of irregular shaped electrodes [24–26], the estimated DEP force 
is predominant for insulin particles, in particular at higher applied electric fields (Figure 
51A), resulting in total insulin velocity (when all other forces are taken into 
consideration) in 0.001–0.1 cm/s range for 1 to 10 V peak-to-baseline AC voltage 
amplitude range (Fig. 4). The effects of other forces, in particular those of Brownian, 
drag, electrothermal, and EO forces, are estimated to be negligible at AC voltages 
exceeding 0.2 V. Effects of Joule electrical heating are estimated to be minimal, reaching 
only ~0.01 °C at 10 V amplitude (Figure 52). Depending on the distance from the 
electrode surface and the applied electric field, the combined electrokinetic forces can 
transport insulin at millimeter-range distances in ~100 s. However, this effect of the DEP 
electrokinetics is only an estimate fully applicable to the particles located ~10 μm from 
the plane of Electrodes 2 and 3, as the predominant DEP force has a relative short-range 
effect. For the particles located further in the bulk solution, the EP force, and the 
concentration driven diffusion, are expected to attract the insulin particles closer to the 
plane of Electrodes 2 and 3. 
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Figure 51:  Simulated balance of DEP (■), EP (X), EO (▲), electrothermal (●), Brownian (⋄ ), 
and drag (□) forces as a function of AC amplitude for: A) insulin; B) terbinafine. 
 
 
In the case of smaller and less polar terbinafine molecules, the DEP force is 
predominant above 1 V (Figure 51B). At lower fields the drag and Brownian forces 
become important. At higher electric fields the terbinafine particles total velocity is 
influenced by a combination of EP and DEP forces achieving total particles velocity in 
0.0001–0.01 cm/s range for 1 to 10 V peak-to-baseline AC voltage amplitude range 
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(Figure 52). Effects of Joule electrical heating were estimated to be minimal, reaching 
~0.002 °C at 10 V amplitude (Figure 51). 
 
Figure 52: Estimated temperature increase for insulin (▯) and terbinafine (●) and total velocities 
for insulin (■) and terbinafine (▲) as a function of AC voltage amplitude. 
 
6.3.2 Insulin and terbinafine delivery results 
Statistical analysis of the results transmembrane transport demonstrated a 5–9 
times increase in the pig skin conductivity for insulin delivery (the mean increase was 
6.78±1.45 times) and a 2–5 times increase in the cow hoof conductivity for terbinafine 
delivery (the mean increase was 3.48±1.25 times) depending on the applied voltage 
amplitudes and frequencies, delivery time, and the membrane's thickness. The literature 
data suggests that AC and DC iontophoretic skin treatments produce reversible increases 
in hydration and disorganization in the lipid bilayers of the stratum corneum, resulting in 
up to three orders of magnitude decrease in the skin electrical resistance and expanded 
skin porosity, leading to higher efficiency of transdermal transport [5–9]. The significant 
conductivity increase was therefore taken as an initial indicator of a more facile drug 
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penetration through the membranes. The statistical analysis demonstrated that this 
conductivity change was driven mostly by the AC voltage amplitude and frequency of the 
applied signal in Circuit 2, and the AC voltage amplitude in Circuit 1 (table 14). The 
membrane's conductivity increase is higher for the lowest (0.1 Hz) frequency value and 
the highest voltage amplitude (10 V) in Circuit 2, in agreement with previously reported 
AC iontophoretic results [17, 18]. Delivery time (in either Circuits 1 or 2) was not found 
to be a significant factor, indicating the conductivity change was driven by the effect of 
the applied electric fields on the membranes, not by the mass transport mechanism. Apart 
from the effects of the AC voltage amplitude that induces polarization and electrokinetic 
transport on the particles, the signal parameters in Circuit 1 appear to be relatively 
unimportant in affecting the membranes' conductivity change. Pre- and post-test pig skin 
and cow hoof conductivity measurements for the control experiments (which applied the 
drug without the electrical signal) showed less than 10% change.  
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Input 
factors 
 
Conductivity, 
Cow hoof 
Conductivity, 
Pig skin 
Throughput, 
Terbinafine 
Throughput, 
Insulin 
Circuit 1 
Time -0.09 +0.11 +0.15 +0.04 
AC voltage 
Amplitude 
+0.37 +0.56 +0.45 +0.69 
Frequency -0.12 -0.06 +0.10 +0.09 
Circuit 2 
Time -0.12 +0.09 +0.05 +0.02 
AC voltage 
Amplitude 
+0.57 +0.66 +0.35 +0.34 
Frequency -0.32 -0.49 -0.45 -0.62 
Membrane 
Thickness 
 N/A -0.25 N/A -0.68 
 
Table 14: R-values for input factors dependence in changes of cow hoof and pig skin 
conductivities and Terbinafine and insulin delivery throughput. 
 
A factor analysis of the investigating variables and one outcome measure 
(membranes' conductivity) finds three significant factors — Circuit 1 voltage, Circuit 2 
voltage, and Circuit 2 frequency variables. The Circuit 1 voltage variable factor explains 
28% (insulin) and 22% (terbinafine) of the variance in the outcome measures, Circuit 2 
voltage factor explains 32% (insulin) and 42% (terbinafine), and Circuit 2 frequency 
explains 22% (insulin) and 24% (terbinafine), for a total of 82% (insulin) and 88% 
(terbinafine) of variance explained by the three factors. This indicates that although the 
study has captured most of the major influential factors, other variables, such as 
membrane thickness that was investigated only in Humalog® 
experiments and showed a moderate (r= −0.25) negative effect on membrane 
conductivity change, also contribute to variations in outcomes. 
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The actual trans-membrane drug delivery was quantified by spectrophotometry 
and GC-MS. A certain degree of uncertainty is expected from the UV–Vis analysis of the 
solutions collected from the receptor compartment, as it detects only the portion of the 
drug passed completely through the entire membrane; an additional portion of the drug 
may be embedded in the membrane. Following the Lamisil transport tests, a residue 
optically comparable to terbinafine was discovered at a receiver chamber side of the 
membranes. GC-MS analysis confirmed the presence of terbinafine with essentially no 
interference from the other Lamisil cream components in this residue. 
Quantification of the terbinafine transport using the developed drug delivery 
model demonstrated the drug delivery to the receiver side of the cow hoof membrane in 
25%–53% range with a statistical mean of 39% based on an initial dose of 1% 
terbinafine. Transport by weight ranged from 1.25 μg to 2.65 μg. When only Electrodes 2 
and 3 were used in the iontophoresis mode at a constant current of 0.2 mA for 1200 s, the 
UV–Vis analysis demonstrated 5.3% transport efficiency, similar to what was reported 
before in the literature on iontophoretic delivery. The passive application of the drug 
resulted in no detectable transport through the cow hoof membrane in 1200 s. 
Quantification of insulin transport through the pig skin membrane demonstrated a 
throughput ranging from 12% to 97%, with a statistical mean of 57% based on an initial 
insulin amount of 2.85 mg in 500 μL sample. Membrane thickness has shown strong 
negative correlation (r= −0.68) with throughput, indicating that thicker membranes are 
more effective in impeding the insulin transport. When only Electrodes 2 and 3 were used 
in the iontophoresis mode at a constant current of 0.2 mA for 1200 s, the UV–Vis 
analysis demonstrated at most 2% transport efficiency (within the error of the UV-
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analysis), indicating essentially no measurable insulin transport. The passive application 
of insulin resulted in no transmembrane transport improvement in 1200 s. Circuit 2 
parameters affecting the transdermal transport were AC voltage and frequency, with 
higher voltage amplitude and lower frequency providing a significant nearly linear 
transport enhancement (Figure 53A), similarly to the previously published data [18]. 
For both experimental sets with Lamisil and Humalog
®
 it was shown that the AC 
frequency values for the electric signals applied in Circuit 1 played essentially no role in 
the effectiveness of the drugs transport. This is not surprising considering that Clausius–
Mossotti polarization factor values for both drugs are positive and constant at frequencies 
under 100 kHz, therefore including all three AC frequency values used in Circuit 1 (1, 
100, and 10,000 Hz) (Figure 50). In compliance with the initial premise that the 
electrokinetic forces increase either proportionally to the electric field or proportionally 
to the gradient of the square of the electric field, increasing the AC voltage amplitude in 
Circuit 1 resulted in an increase in throughput from 7±2% (0.1 V) to 40±13% for 
terbinafine transport (10 V) in 1200 s. Increasing of the AC amplitude from 0.1 V to 10 V 
(Humalog
®
) resulted in the increase in throughput from 10±2% to 74±20% for insulin 
transport in 1200 s. Figure 53 illustrates this point by presenting the data samples for the 
experiments where the thickness of the membranes was held constant at 1 mm, 
operational times for both Circuits 1 and 2 at 1200 s, Circuit 1 AC frequency at 1000 Hz, 
Circuit 2 AC frequency at 0.1 Hz, and Circuit 2 voltage peak-to-baseline amplitudes 
variable between 1 and 10 V. Delivery times for Circuit 1 played little role in the 
effectiveness of the drugs delivery, showing weak positive correlation (r=0.04 for insulin, 
r=0.15 for terbinafine) with throughput, indicating that longer delivery times are 
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somewhat more effective in increasing drug transport. Relative weakness this correlation 
may be related to one of the computational analysis conclusions indicating that a time 
period of ~100 s is largely sufficient for polarization and transport of both drugs (in 
particular insulin) to the edges of Electrodes 2 and 3. 
Apart from the effects of the voltage amplitudes in Circuits 1 and 2, and low 
frequency values in Circuit 2 for both investigated drugs, and membrane thickness in 
Humalog
®
 studies, the investigating variables did not strongly correlate with throughput, 
which was fairly consistent across study parameters. For example, for the insulin studies 
half of the throughput values were between 40% and 70%, and three quarters were 
between 40% and 100%. The standard deviation for throughput was 22%. 
Application of higher AC electric fields can potentially cause a heating Joule 
effect, especially if the media possesses abnormally high electrical and low thermal 
conductivities. The temperature readings of the skin surface before, during and after each 
experimental study demonstrated essentially no localized heating or visible damage to 
membranes (such as burns) due to the application of the electrical fields, consistent with 
the conclusions derived on the basis of the computational model (Figure 52).  
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Figure 53:  Drug delivery throughput results and variation by AC voltage amplitude in Circuit 1 
for: A) insulin and B) terbinafine for the membranes thickness of 1 mm, Circuit 1 and Circuit 2 
delivery times 1200 s, Circuit 1 AC frequency of 1000 Hz and Circuit 2 AC frequency of 0.1 
Hzwere constant, Circuit 2 voltageamplitudes (■,■)10 Vand1 V(▲,▲). Iontophoresis results at 
0.2 mA constant current (♦, ♦) are shown for comparison. 
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Even for 10 V peak-to-baseline voltage amplitude in Circuit 2, the resulting AC 
currents did not exceed 5 mA (peak-to-baseline), which is a threshold based on human 
tolerance to these currents from the in vivo studies [19]. A comparable study in the 
literature showed that a low voltage current at 1 V for 1 min across the stratum corneum 
 10 μm thick and resistance 100 k Ohm/cm) gave rise to a very moderate 0.14 °C 
temperature increase [5]. However, this model assumes that all electrical energy is 
dissipated and converted into heat in the skin and generally provides an overestimate in 
the temperature rise. On the other hand, in the iontophoretic delivery a precaution should 
always be taken to keep the voltage amplitudes reasonably low while keeping the 
transdermal flux high. Due to the heterogeneity of the stratum corneum structure and 
composition, current could flow through localized pathways and dissipation of the energy 
could result in localized heating underestimated by calculation. 
Development of microfabricated 3D interdigitated electrodes allows for a higher 
throughput drug delivery system as the EP and DEP effects are enhanced. These types of 
interdigitated devices show less of a decrease in the force profile with the distance above 
the plane, therefore greatly improving the polarization effect and transport of the 
particles. The interdigitated 3D electrodes structure also showed approximately 10 times 
smaller Joule heating effect for similar conditions when compared with a 2D planar 
electrodes structure [27]. 
Our results indicate that utilization of electric field in iontophoretic or 
electroporation skin treatment, even when strong enhancement in the skin conductivity is 
achieved, is insufficient for an effective transdermal delivery. The significant increase in 
the membrane conductivity is not always indicative of the efficient drug transport through 
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the membrane. In fact, the several studies with highest membranes conductivity increase 
(up to 10 times) had relatively low throughput values, including the lowest value 
recorded of 12% insulin throughput. The pathway of ion transportation induced by AC 
electrokinetic forces may be somewhat different from that induced by DC iontophoresis 
[17]. Non-facilitated transport across the skin can conceivably occur via transcellular, 
paracellular, or appendageal paths [28]. Transport pathways are influenced by 
physicochemical factors (molecular size, electric charge, concentration) and biological 
factors (skin site, morphological structure, regional blood flow). Although our study does 
not reveal the nature of the major transportation pathway during the AC electrokinetic 
delivery of terbinafine and insulin, their molecules may be transported through not only 
an appendageal path, but also a transcellular path. Additionally, we cannot deny the 
possibility that an AC electric field with a certain frequency may directly open a new 
pathway, leading to facilitation of ion transportation. Since structural changes in the 
biological membranes during the application of AC electrokinetic treatment were not 
examined in the present study, further research is needed to determine the major 
transportation pathway evoked by the AC field in different biological membranes. The 
effects of different biological membranes, including the human skin, will be addressed in 
the future, including the effects of membrane's heterogeneity and ageing.  
 
6.4 Conclusions 
Our results indicated that a combination of two applied AC fields generating 
electrokinetic and iontophoretic protocols was capable of in vitro transporting clinically 
significant amounts (50–90% throughput levels) of macromolecular insulin and non polar 
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terbinafine across membranes up to 2 mm thick in as little as several minutes, which is a 
significant improvement over macromolecular transdermal delivery results reported in 
the literature. On average, a combination of electrokinetic and iontophoretic protocols 
achieved transdermal delivery enhancement of ~28 times for insulin and ~7 times for 
terbinafine comparing to the iontophoretic constant current mode, and even better 
enhancement over the passive diffusion transdermal drugs application. This adaptable 
new method of drug transport was capable of motivating chemical compounds that are 
difficult to transport non invasively because of their large molecular size and non ionic 
structure. This is accomplished through the use of electrokinetic forces in interdigitated 
electrodes applying a non uniform AC electric field to a chemical compound, inducing an 
electrical field gradient that provides an electromotive force variable in magnitude and 
direction with applied frequency and field strength. Macromolecular drugs are thus 
polarized, and their iontophoretic transmembrane delivery is controlled by a second AC 
field. Applied AC voltage amplitude which polarizes the drugs, AC voltage amplitude 
and frequency inducing iontophoretic and electroporation effects, and the 
membrane's thickness were the most significant factors in affecting the throughput. 
It is important to state that stand alone constant current iontophoretic mode 
application unsupported by electrokinetic polarization and manipulation of the drugs was 
generally unsuccessful in transdermal transport of insulin and terbinafine. Therefore the 
iontophoretic and electroporation enhancements of transmembrane delivery should be 
combined with electrokinetic polarization of non polar macromolecular drugs. The full 
magnitude of effects of the electrodes geometry and polarity; delivery time; medication 
chemical properties and composition; type, hydration, porosity, surface charge and 
 xxix 
 
condition of biological tissue membranes; AC voltage amplitude and frequency on the 
efficiency of the electrokinetic drug transport is yet to be investigated. Continuing our 
work in optimization of combination (either sequential or simultaneous operation) of 
optimally- tuned AC electrical fields is needed for inducing polarization and enhancing 
transport to deliver macromolecules through biological membranes. On the basis of these 
principles, a non-invasive transdermal method capable of delivering non polar high 
molecular weight drugs appears to be feasible. This method has a potential for producing 
clinical products for efficient, facile, controlled and safe transdermal drug delivery. 
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